



(11) **EP 1 208 231 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
10.01.2007 Bulletin 2007/02

(21) Application number: **00936765.7**

(22) Date of filing: **04.05.2000**

(51) Int Cl.:
C12Q 1/68 (2006.01)

(86) International application number:
PCT/EP2000/004591

(87) International publication number:
WO 2000/068424 (16.11.2000 Gazette 2000/46)

(54) **MEANS FOR DETECTING AND TREATING PATHOLOGIES LINKED TO FGFR3**

MITTEL ZUM NACHWEIS UND ZUR BEHANDLUNG VON KRANKHEITEN DIE IN VERBINDUNG STEHEN MIT FGFR3

MOYENS DE DETECTION ET DE TRAITEMENT DES PATHOLOGIES ASSOCIEES AU FGFR3

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: **05.05.1999 US 132705 P**

(43) Date of publication of application:
29.05.2002 Bulletin 2002/22

(73) Proprietors:
• **Institut Curie**
75248 Paris Cedex 05 (FR)
• **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)**
75794 Paris Cedex 16 (FR)

(72) Inventors:
• **CAPPELLEN, David**
F-14810 Merville-Franceville (FR)
• **CHOPIN, Dominique**
F-94000 Creteil (FR)
• **RADVANYI, François**
F-92260 Fontenay-aux-Roses (FR)
• **RICOL, David**
F-75013 Paris (FR)
• **THIERY, Jean-Paul**
F-75013 Paris (FR)

(74) Representative: **Peaucelle, Chantal et al**
Cabinet Armengaud Aîné
3, Avenue Bugeaud
75116 Paris (FR)

(56) References cited:

- **CHESI, M. ET AL.:** "Frequent translocation t(4;14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3" **NATURE GENETICS**, vol. 16, no. 3, 1997, pages 260-264, XP001030990
- **WEBSTER, M. K. ET AL.:** "Enhanced Signaling and Morphological Transformation by a Membrane-Localized Derivative of the Fibroblast Growth Factor Receptor 3 Kinase Domain" **MOL. CELL. BIOL.**, vol. 17, no. 10, 1997, pages 5739-5747, XP002181674
- **LI, Z. H. ET AL.:** "An activating mutation of the myeloma associated oncogene fibroblast growth factor receptor 3 (FGFR3) has hematopoietic transforming potential in mice" **BLOOD**, vol. 92, no. 10, Suppl 1 (Part 1 of 2), 15 November 1998 (1998-11-15), page 383A XP001030987
- **PLOWRIGHT, E.E. ET AL.:** "An activating mutation of the myeloma associated oncogene fibroblast growth factor receptor 3 (FGFR3) promotes interleukin-6 (IL-6) independence and upregulation of bcl-xL" **BLOOD**, vol. 92, no. 10, Suppl 1 (Part 1 of 2), 15 November 1998 (1998-11-15), page 383A XP002181675
- **CAPPELLEN, D. ET AL.:** "Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas" **NATURE GENETICS**, vol. 23, September 1999 (1999-09), pages 18-20, XP002181676
- **FENG ET AL.:** **CANCER RESEARCH**, vol. 57, no. 23, 1 December 1997 (1997-12-01), pages 5369-5378,
- **DENG ET AL.:** **CELL**, vol. 84, no. 6, 22 March 1996 (1996-03-22), pages 911-921,

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 208 231 B1

- WANG ET AL.: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 96, no. 8, 13 April 1999 (1999-04-13), pages 4455-4460,
- SU ET AL: NATURE, vol. 386, no. 6622, 20 March 1997 (1997-03-20), pages 288-292,

Description

[0001] The invention relates to means, i.e. method and drugs, for detecting and treating, respectively, pathologies linked to FGFR3 and/or to the FGFR3 pathway.

[0002] Fibroblast growth factor receptor 3 (FGFR3) belongs to a family of structurally related tyrosine kinase receptors (FGFRs 1-4) encoded by four different genes. These receptors are glycoproteins composed of two to three extracellular immunoglobulin (Ig)-like domains, a transmembrane domain and a split tyrosine-kinase domain. Alternative mRNA splicing results in many different receptors variants. Isoforms FGFR3-IIIb and FGFR3-IIIc result from a mutually exclusive splicing event in which the second half of the juxtamembrane Ig-like domain is encoded either by the 151 nucleotides long exon 8 (IIIb variant) or the 145 nucleotides long exon 9 (IIIc variant).

[0003] Specific point mutations in the *FGFR3* gene which affect different domains of the protein are associated with autosomal dominant human skeletal disorders such as hypochondroplasia, achondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans and thanatophoric dysplasia. Several reports have demonstrated that these mutations lead to constitutive activation of the receptor. Taking into account this result, together with the skeletal overgrowth observed in mice homozygous for null alleles of *Fgfr3*, FGFR3 appears as a negative regulator of bone growth.

[0004] In contrast with this inhibitory role, an oncogenic role has been proposed for *FGFR3* in multiple myeloma (MM) development. In this malignant proliferation of plasma cells, a t(4;14)(p16.3;q32.3) chromosomal translocation with breakpoints located 50 to 100 Kb centromeric to *FGFR3* is present in 20-25% of the cases and is associated with overexpression of FGFR3.

[0005] In very rare cases (2 out of 12 MM cell lines and 1 out of 85 primary MM tumours), activating mutations of *FGFR3* previously identified in human skeletal disorders have been found, but always accompanied by the t(4;14)(p16.3;q32.3) translocation.

[0006] By investigating various cancers, the inventors have surprisingly found a role for FGFR3 in cancers originating from epithelial tissues, carcinomas.

[0007] The involvement of FGFR3 in such solid tumour development is linked to a constitutional activation : it may be activated by an autocrinal loop (ligand self-production) and/or by activating mutations in *FGFR3*. Surprisingly, such mutations are found in primary tumours and are somatic mutations (genomic DNA mutations).

[0008] So far, the only FGFR3 isoform which has been identified in epithelium is the FGFR3-IIIb isoform.

[0009] The invention thus relates to a method and kits for detecting carcinomas.

[0010] According to another aspect, the invention also relates to the manufacture of drugs capable of treating carcinomas.

[0011] According to still another aspect, it relates to transgenic animals enabling the efficiency of such drugs to be tested.

[0012] The method of the invention for detecting carcinomas in a biological sample comprises identifying FGFR3 mutations.

[0013] Standard methods can apply for such an identification such as immunohistochemistry, or detection of the corresponding RNA, DNA, and encoded protein contained in said sample, particularly after extraction thereof. A common way for such a detection comprises amplifying by PCR, RT-PCR or RT-PCR SSCP (single strand conformation polymorphism) with *FGFR3* specific primers and revealing the amplification products according to the usual methods. A corresponding embodiment is exemplified in the examples given hereinafter. Another common way comprises the use of antibodies and the detection of the antigen-antibody reaction with appropriate labelling.

[0014] The activating function of a mutation can be determined by observation of activating signals such as receptor phosphorylation, cell proliferation (e.g. thymidine incorporation) or indirect effects such as calcium influx, phosphorylation of target sequences.

[0015] More particularly, said identification comprises screening for single nucleotide mutation(s) in the genomic DNA and/or its products, i.e. RNA, protein, the term "product" also encompassing cDNA.

[0016] Particularly, said method comprises screening for mutations creating cysteine residues in the extracellular or transmembrane domains of the receptor.

[0017] Alternatively, or in combination with the foregoing embodiment, it comprises screening for mutations resulting in at least one amino-acid substitution in the kinase domain of the receptor.

[0018] It particularly comprises screening of activating mutation(s) of FGFR3, notably such as above-described.

[0019] More particularly, the method of the invention comprises screening for mutation(s) in exon 7, encoding the junction between immunoglobulin-like domains II and III of FGFR3, in exon 10, encoding the transmembrane domain, in exon 15, encoding the tyrosine kinase domain I, and/or in the exon encoding the C-terminal part.

[0020] Advantageously, the method of the invention comprises screening for missense mutations such as implicated in thanatophoric dysplasia, NSC, achondroplasia, sattan, or hypochondroplasia.

[0021] Such FGFR3 mutations notably comprise R248C, S249C, G372C, S373C, Y375C, K652E, K652M, J809G, J809C, J809R, J809L, P250R, G377C, G382R, A393E, N542K (codons are numbered according to FGFR3-IIIb cDNA open reading frame).

[0022] The following FGFR3 mutations will be particularly identified : R248C, S249C, G372C, K652E and Y375C.

[0023] Said biological sample used in the method of the invention will advantageously comprise a tissue, bone marrow, or a fluid such as blood, urine, deriving from a warm-blooded animal, and more especially from a human.

[0024] Said method is particularly useful for detecting carcinomas, such as human bladder and cervix carcinomas. A major issue in superficial bladder cancer is to distinguish tumours which will progress from those which will not. Insights into the genetic and epigenetic alterations involved in bladder cancer is expected to provide useful information to facilitate this distinction. In that respect, the invention provides means to resolve the dilemma between a bladder-sparing strategy versus cystectomy and will contribute to a more individualised intravesical instillation and endoscopic monitoring policy.

[0025] Indeed, as shown by the results given in the examples, *FGFR3* appears to be a major oncogene in Ta, T1 bladder carcinomas. The *FGFR3* mutations appear to be frequently associated with tumours that do not progress. Multivariate analysis showed that *FGFR3* mutation status remained a statistically significant predictor of good outcome. *FGFR3* mutations thus provide clear-cut information, which may complement stage and grade. The use of these mutations alone and/or in combination with other predictors of tumour aggressiveness will then provide relevant prognostic information.

[0026] Said method, will also be used for detecting for example lung, breast, colon, skin cancers.

[0027] The method of detection according to the invention applies to the diagnostic of carcinomas, as well to the prognosis, or the follow-up of the efficiency of a therapy.

[0028] Said method will advantageously be performed by using kits comprising the appropriate reagents and a notice of use.

[0029] According to another aspect, the invention relates to the manufacture of drugs having an anti-proliferative effect on carcinoma cells. Such drugs comprise, as active principle(s) agent(s) which act by inhibition of FGFR3 DNA synthesis or by inhibition of its expression products (RNA, proteins). Particularly, such drugs contain tyrosine kinase inhibitors specific for FGFR3.

[0030] Other appropriate inhibitors comprise antibodies directed against FGFR3, and particularly against at least one extracellular Ig-like domain thereof. Advantageously said antibodies are specific for FGFR3-IIIb. Preferred antibodies are monoclonal ones, and particularly antibodies modified so that they do not induce immunogenic reactions in a human body (e.g. humanized antibodies).

[0031] Other appropriate inhibitors comprise antisense oligonucleotides directed against a wild or mutated *FGFR3* isoform.

[0032] The administration and the posology of said inhibitors will be determined by the one skilled in the art depending on the carcinoma to be treated, the weight and age of the patient. For example, antibodies will be administered by the injectable route.

[0033] The invention thus gives means of great interest for detecting and treating carcinomas, taking into account the fact that cancers originating from epithelial tissues (carcinomas) represent approximately 90 % of malignant neoplasms.

[0034] Disclosed are cell lines capable of expressing FGFR3 mutated forms. Particularly, disclosed are FGFR3 S249C mutated forms. T24 cell lines constitutively expressing FGFR3 S249C mutated forms and HeLa cell lines expressing FGFR3 S249C mutated forms in an inducible manner have thus been obtained (for example see ref.(6)).

[0035] By injecting such cell lines to nude mice, an increased tumorigenicity was observed.

[0036] Such cell lines are useful *in vitro* (follow up of the receptor phosphorylation) or *in vivo* (examination of the tumorigenicity of nude mice) to study the inhibitor effect against FGFR3.

[0037] Cell lines transfected with FGFR2, FGFR1 or FGFR4 are particularly useful for studying the specificity of inhibitors to be tested.

[0038] According to still another object, the invention relates to constructions capable of expressing by transgenesis a FGFR3 mutated form in epitheliums and the transgenic animals thus obtained which are characterized by the fact that they comprise such constructions.

[0039] Examples of constructions intended for injection in animal germinal cells comprise a keratin promoter, particularly keratin 14 promoter and cDNA of mutated FGFR3.

[0040] Other advantages and characteristics of the invention will be given in the following examples wherein it will be referred to

- figures 1A - 1B which give FGFR3-IIIb gene activating mutations in primary tumours,
- figures 2A - 2E which refer to FGFR3-IIIb wild (2A) and mutated pro-oncogenic (2B-2T) sequences. It will be noted that the sequences of figures 2B to 2T, as such, enter into the scope of the invention. There may be silent polymorphisms all along the sequence, so there may be in fact several possible sequences for each mutant, and
- figures 3a and 3b which respectively represent a) Kaplan-Meier progression-free survival curves according to *FGFR3* mutations (dotted line: mutated *FGFR3*, solid line: non-mutated *FGFR3*; log rank test $p=0.014$) ; b) Kaplan-Meier disease-specific survival curves according to *FGFR3* mutations (dotted line: mutated *FGFR3*, solid line: non-mutated *FGFR3*; log rank test $p=0.007$)

Example 1 : *FGFR3* gene mutations in bladder and cervix carcinomas

[0041] *FGFR3-IIIb* and *FGFR3-IIIc* transcript levels were examined by reverse transcription-polymerase chain reaction (RT-PCR) in 76 primary bladder carcinomas and 29 primary invasive cervical carcinomas.

[0042] *FGFR3-IIIb*, the sole isoform to be significantly expressed, was detected in 72 out of 76 (94%) bladder carcinomas and 27 out of 29 (93%) cervical carcinomas.

[0043] A PCR-SSCP analysis was then conducted on both reverse transcribed RNA and genomic DNA to screen for *FGFR3* coding sequence variants in 26 bladder and 12 cervix cancers expressing the gene. The results are illustrated in figures 1a and 1b which gives the identification of *FGFR3* gene mutations in human carcinomas :

- a: gives the identification of somatic mutations by direct sequencing of PCR products. Normal constitutional DNA; Tumour, tumour DNA.
- b: gives *FGFR3* mutations associated with skeletal disorders and cancers.

[0044] The schematic structure of *FGFR3* is depicted (Ig I-III, immunoglobulin like domains ; TM, transmembrane domain ; TK-1 and -2, tyrosine kinase domains) and the locations of the known human missense mutations associated with thanatophoric dysplasia (TD) and severe achondroplasia (SADDAN), bladder and cervix carcinomas (carc.) and multiple myeloma (MM) are indicated. Usual amino acid abbreviations are used to point out the mutation found in each pathological situation. The mutations at codon 807 incriminated in TD replaces a Stop codon (J) by an amino acid (G, C, R or L) and the mRNA thus continues to be translated until another in-frame Stop codon is reached 423 nucleotides downstream thus leading to a 141 amino acid longer protein.

[0045] Abnormally migrating bands were observed for certain samples (Fig. 1a) and direct sequencing of PCR products revealed single nucleotide substitutions in 9 out 26 bladder carcinomas (35 %) and 3 out of 12 (25 %) cervix carcinomas (Fig. 1b and table 1).

Table 1

Summary of <i>FGFR3</i> gene mutations in primary bladder and cervix cancers					
Sample	Histopathol.	Codon	Nt Position	Mutation	Predicted effect
1447, bladder	carc., Ta G2	249	746	TCC to TGC	Ser to Cys
342, bladder	carc., T1a G1	249	746	TCC to TGC	Ser to Cys
813, bladder	carc., T1a G1	372	1114	GGC to TGC	Gly to Cys
1393.1, bladder	carc., T1a G3	249	746	TCC to TGC	Ser to Cys
506, bladder	carc., T1b G2	372	1114	GGC to TGC	Gly to Cys
1084, bladder	carc., T1b G3	652	1954	AAG to GAG	Lys to Glu
745.1, bladder	carc., T2 G3	248	742	CGC to TGC	Arg to Cys
1077, bladder	carc., T3 G2	249	746	TCC to TGC	Ser to Cys
1210, bladder	carc., T3 G2	249	746	TCC to TGC	Ser to Cys
4.13, cervix	carc., stage II	249	746	TCC to TGC	Ser to Cys
4.139, cervix	carc., stage II	249	746	TCC to TGC	Ser to Cys
6.96.1, cervix	carc., stage II	249	746	TCC to TGC	Ser to Cys
Histopathol., histopathological classification of the tumours (carc., carcinoma: TNM and HUGO classifications are used respectively for bladder and cervix cancers) ; codon and mutated nucleotide (Nt position) are numbered according to <i>FGFR3-IIIb</i> cDNA open reading frame.					

[0046] Mutations were found in the following exons

- exon 7, encoding the junction between immunoglobulin-like domains II and III of *FGFR3* (one C-to-T transition at codon 248 in patient 745.1 and a C-to-G substitution at codon 249 in patient 1447) ;
- exon 10, encoding the transmembrane domain (a G-to-T-transversion at codon 372 in patient 813)
- exon 15, encoding the tyrosine kinase domain II (a A-to-G transition at codon 652 in patient 1084).

[0047] Analysis of matched constitutional DNA from the patients for which such material was available (n=8) demonstrated the somatic nature of these *FGFR3* mutations (Figure 1).

[0048] Strikingly, each of the *FGFR3* missense mutations identified herein, i.e. R248C. S249C. G372C and K652E.

are implicated in thanatophoric dysplasia (TD). Given the presence of two additional amino-acids in the IIIb isoform expressed in epithelial cancers as compared to the IIIc isoform expressed in bone, the G372C and K652E mutations are indeed equivalent to the G370C and K650E mutations responsible for TD.

[0049] The S249C mutation was the most commonly observed, affecting 5 out of 9 (55 %) bladder cancers and all of the cervical cancers (3 out of 3, 100 %) in which *FGFR3* gene alterations have been identified so far.

[0050] The R248C, S249C and G372/370C mutations create cysteine residues in the extracellular or transmembrane domains of the receptor and the K652/650E mutations results in amino-acid substitution in the kinase domain of the receptor.

Example 2 : Inhibitors

[0051] A way to test the different FGFR3 inhibitors comprises transfecting cell lines so that they express the mutated forms of FGFR3, or wild type FGFR3 or just the neomycin or hygromycin resistant gene under the control of a strong promoter, such as CMV, RSV, SV40 promoters. The tumorigenic properties of these cell lines can then be compared *in vitro* or *in vivo* in nude mice. The different inhibitors will be tested *in vitro* or *in vivo* using these different cell lines. Phosphorylation, proliferation or indirect effects of FGFR3 such as calcium influx will be measured. Transgenic mice expressing in various epithelia the mutated FGFR3 can thus be derived thereof. Those mice developing tumours are useful tools for testing the efficiency of candidate inhibiting drugs. Such transgenic animals fall also into the scope of the present invention.

Example 3 : FGFR3 mutations in Ta, T1 tumours in bladder cancer.

[0052] Bladder cancer is a disease with a spectrum of forms and is highly unpredictable. At the time of initial diagnosis, approximately 80% of patients present with a superficial tumour. Superficial bladder cancers include carcinoma *in situ* (Tis), Ta and T1 lesions (TNM classification). Ta/T1 lesions are mostly papillary urothelial carcinomas: Ta lesions do not invade the basement membrane, whereas T1 lesions invade the lamina propria, but do not invade the detrusor muscle of the bladder wall. Carcinoma *in situ* are flat, cytologically high-grade carcinomas, confined to the urothelium. Primary isolated carcinoma *in situ* is a very rare entity and is more commonly associated with Ta/T1 lesions. Despite transurethral resection alone or combined with adjuvant intravesical therapies, more than one half of patients with Ta/T1 tumours suffer recurrences. In most cases, recurrences are also superficial, but about 5% of Ta and 30-50% of T1 tumours progress in an unpredictable manner to muscle invasion with a high risk of development of metastases and death from bladder cancer.

[0053] The management of superficial bladder cancer is based on clinicopathological parameters. Three groups of tumours can be defined. of low, intermediate and high risk, according to their potential for recurrence and progression. This classification is used to recommend adjuvant intravesical therapies and bladder monitoring, but it is not a sufficiently sensitive discriminant for use in determining the appropriate treatment and mode of surveillance for a given patient. Although Bacille Calmette-Guérin (BCG) therapy appeared to be the most effective regimen for the high-risk group, long-term results indicate that progression occurs in 40% by 10 years and in more than 50% by 15 years. For some researchers, these findings justified the use of up-front radical cystectomy in high-risk superficial urothelial carcinomas, despite the risk of overtreating a significant number of patients. Follow-up of Ta and T1 superficial bladder cancers constitutes most of the workload of urologists involved in the management of bladder cancer. The current strategy is based on frequent cystoscopic evaluations using a schedule that is largely empirical, without considering the individual characteristics of the tumour.

[0054] The limitations of the current management of bladder cancer demonstrate the need for prognostic markers, making possible the use of selective aggressive treatments for patients at high risk of progression while sparing low-risk patients from unnecessary procedures. A number of chromosomal loci and specific genes have been implicated in bladder tumorigenesis. Losses of all or part of chromosome 9 in many TaG1 tumours suggests that the inactivation of a gene or genes on chromosome 9 may be an early event in urothelial transformation. The prognostic significance of losses on chromosome 9 is unclear. Alterations of the *P53* and *RB* genes controlling the G1 cell cycle checkpoint have been clearly delineated and are associated with the aggressiveness of superficial and invasive bladder cancers. Despite these recent insights into the molecular mechanisms of bladder carcinoma progression, these markers have not yet had any impact on clinical practice.

[0055] The following assays have been performed to assess the reliability, as markers, of the FGFR3 mutations.

Material and method

Patients and tissue samples

5 **[0056]** Seventy four specimens of superficial Ta, T1 bladder carcinomas were obtained from 74 patients by transurethral resection performed at the Henri Mondor hospital, Créteil, France, from January 1988 to December 1998. Tumours were staged according to the TNM classification (1) and graded according to criteria recommended by the World Health Organisation (2). This series consisted of 25 pTa and 49 pT1 tumours, with 28 grade G1, 33 grade G2 and 13 grade G3 tumours. The 64 men and 10 women had a mean age of 64 years (range: 29 to 94 years). None of the patients had any detectable distant metastases at the time of transurethral resection. Patients were treated by transurethral resection (TUR) alone (n=25), TUR followed by mitomycin C instillation (n=10) or TUR and BCG (n=39) according to the French Committee for Urologic Oncology (CCAFU) recommendations. There was no change in the policy for treating superficial bladder cancer during the study period. Progression was defined as the occurrence of a pT2 or higher stage or appearance of lymph node invasion or metastasis or death from cancer. Disease-specific survival curves were plotted using death from urothelial cancer as the endpoint. Follow-up was based on systematic cystoscopy and cytology, and imaging studies only when indicated. All outpatient visits and hospital admissions were recorded in a database from which the study data were calculated.

10 **[0057]** Tumour DNA was extracted from formalin-fixed and paraffin-embedded tissue or samples freshly frozen in liquid nitrogen (4). Normal DNA samples from peripheral blood were available for 27 patients.

20

FGFR3 mutation analysis

25 **[0058]** Mutations in the *FGFR3* gene were detected by SSCP analysis. Exons 7, 10, 15 and 20 of the *FGFR3* gene were analysed because these exons harbour all the mutations previously identified in bladder carcinomas and thanatophoric dysplasia. All mutations detected by SSCP analysis were confirmed by direct bidirectional sequencing of tumour genomic DNA. Matched normal DNA, if available, was sequenced on both strands to demonstrate the somatic nature of these mutations.

Statistical methods

30

35 **[0059]** Associations between *FGFR3* mutation status and other data (sex, age, stage and grade) were tested using χ^2 and Student's t tests. Progression-free and disease-specific survival curves were plotted using Kaplan-Meier estimates. Survival distributions were compared using the log-rank test. Cox's proportional hazards regression model was used to test the effect of mutations, while simultaneously accounting for baseline patient and tumour characteristics. The influence of the covariates on the *FGFR3* mutation effect was assessed in multivariate analysis involving a forward stepwise procedure and a backward stepwise procedure, using the MPRL (maximum partial likelihood ratio) method. The limit to enter a term was 0.15 and the limit to remove a term was 0.10. Statistical analyses were performed using BMDP® and S-Plus® software.

40 **Results**

[0060] *FGFR3* missense mutations were observed in 41 of the 74 (55%) Ta, T1 bladder tumours. The *FGFR3* mutations found are described in Table 2 below :

45

Table 2

Number of tumours (%)	Codon*	nt position*	Mutation	Predicted effect
5(12%)	248	742	CGC -> TGC	Arg -> Cys
28(68.5%)	249	746	TCC -> TGC	Ser -> Cys
5(12%)	372	1,114	GGC -> TGC	Gly -> Cys
2(5%)	375	1,124	TAT -> TGT	Tyr -> Cys
1 (2.5%)	652	1,954	AAG -> GAG	Lys -> Glu
* codon and mutated nucleotide (nt position) are numbered according to FGFR3-IIIb cDNA open reading frame. FGFR3-IIIb is the isoform expressed in epithelial cells.				

55

[0061] S249C was the commonest mutation and was found in 16 of the 21 (76%) mutated Ta tumours and 12 of the 20 (60%) mutated T1 tumours. Matched constitutional DNA, available in 15 of the cases of tumour with mutations, contained wild-type sequences, demonstrating the somatic nature of these mutations.

[0062] The correlation between sex, age, stage, grade and *FGFR3* mutation status is given Table 3 :

Table 3

	<i>FGFR3</i> wild type	<i>FGFR3</i> mutant	p value (χ^2 or Student's t test)	
Sex				
Male	29	35		
Female	4	6	0.9779	
Age (years)				
mean	64.30	63.22		
range	[29.15-86.10]	[34.3-94.4]	0.7393	
Stage				
Ta	4	21		
T1	29	20	0.001	
Grade				
G1	7	21		
G2	14	19		
G3	12	1	0.0003	

[0063] Statistically significant correlations were observed between *FGFR3* mutations and low stage (p=0.001) and low grade (p=0.0003), but not between these mutations and age or sex (Table 2).

[0064] With a median follow-up of 4.3 years (range: 6 months to 11 years), 3 patients progressed and one died in the mutated tumour group (n=41 patients) whereas ten patients progressed and eight died in the non-mutated tumour group (n=33 patients). The median follow-up was 5.6 years (range: 7 months to 11 years) in the non-mutated group and 4.1 years (range: 6 months to 9 years) in the mutated group.

[0065] To examine *FGFR3* mutations as a marker of patient outcome, we calculated Kaplan-Meier progression-free survival and disease-specific survival probability curves for the two groups of patients and examined the differences using the log rank test. Progression-free and disease-specific survival indicated that *FGFR3* mutations were associated with a lower risk of progression (p=0.014) and longer survival (p=0.007) (Figure 3). We tested several variables (age, sex, stage, grade) but only stage was significantly associated with progression and survival in univariate analysis. If only T1 patients were analysed, the correlation was still significant for disease-specific survival (p=0.03) and close to significance for progression-free survival (p=0.052).

[0066] Multivariate analysis was used to determine whether the correlation between *FGFR3* mutation status and progression-free survival or disease-specific survival was independent of other outcome predictors. For progression-free survival, the following covariates were introduced into the Cox model: mutation, stage, grade and sex. For disease-specific survival, mutation and grade were the only covariates introduced into the model, as no disease-related deaths were observed among female or Ta patients. If *FGFR3* status was entered into the model, neither stage nor grade provided any additional prognostic value for tumour progression. In the analysis of disease-specific survival, *FGFR3* mutation was also the only covariate to be entered into the model, as grade did not provide any additional prognostic information. Relative risks and their 95% confidence intervals (CI) are shown in Table 4.

Table 4

	Progression		Disease-specific Survival	
	Relative Risk	95% CI	Relative Risk	95% CI
<i>FGFR3</i>				
Wild-type	1		1	
Mutant	0.23	(0.06; 0.83)	0.10	(0.01; 0.80)

EP 1 208 231 B1

(continued)

Progression		Disease-specific Survival	
Relative Risk	95% CI	Relative Risk	95% CI
Other variables do not significantly contribute to the model			
Forward and backward procedures both yielded the same model. As shown by the above results, the FGFR3 activating mutations were frequent in bladder carcinomas.			

[0067] All the carcinomas having a mutated receptor expressed said receptor at levels similar or above those observed with normal tissues. Immunohistochemical methods will then advantageously be used for revealing the receptor.

[0068] FGFR3 mutation detection in bladder carcinomas appears to be a good prognostic, giving then to the clinicians valuable means for treating and observing carcinomas, which represent a medical problem due to the high frequency of recurrences.

[0069] By using SSCP or PCR coupled to an enzymatic restriction S249C mutation specific (which represent 75% of the mutations) on patients having bladder carcinomas with S249C mutation, the mutation could be detected in urine in 60% of the cases.

Example 4: Detection of FGFR3 mutations in patients' urines

[0070] Genomic DNA is extracted from patients' urines and amplified by PCR, in the presence of ³²P- labelled dCTP, using standard methods. The following primers were used for detecting S249C mutation :

5'-CAG CAC CGC CGT CTG GTT GG-3' and 5'-AGT GGC GGT GGT GGT GAG GGA G-3'.

30 cycles of PCR are performed.

The amplification products are digested by *Cac8I*. An additional site is created by *FGFR3* mutation and a corresponding band is observed on an electrophoretic gel.

[0071] Similarly the following primers and enzymes can be used to detect:

R248C mutation:

Primers : 5'-TGT GCG TCA CTG TAC ACC TTG CAG-3' and 5'-AGT GGC GGT GGT GGT GAG GGA G-3'

Enzyme : *Bsi* HKA I

K652E mutation :

Primers : 5'-TGG TGA CCG AGG ACA ACG TGA TG-3' and 5'-AGG GTG TGG GAA GGC GGT GTT G-3'

Enzyme : *Bsm* A I

G372C mutation:

Primers : 5'-CCT CAA CGC CCA TGT CTT TTC AGC-3' and 5'-CTT GAG CGG GAA GCG GGA GAT CTT G-3'

Enzyme: *Pst* I

Y375C mutation:

Primers : 5'-CCT CAA CGC CCA TGT CTT TTC AGC-3' and 5'-CTT GAG CGG GAA GCG GGA GAT CTT G-3'

Enzyme: *Bsg* I

References

[0072]

1. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. *Cancer* 1997; **80**: 1803-4.

2. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. *Am J Surg Pathol* 1998; **22**: 1435-48.

3. Rischmann P, Bittard H, Chopin D, et al. Tumeurs Urothéliales. *Prog Urol* 1998; **8**: 25-50.

EP 1 208 231 B1

4. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. *Oncogene* 1997; **14**: 3059-66.

5. Cappellen D, De Oliveira C, Ricol D, Gil Diez de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nature Genetics*, vol 23, sept. 1999.

6. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. *Science* 1995 ; **268** : 1766-9.

LISTE DE SEQUENCES

[0073]

15 <110> INSTITUT CURIE
C.N.R.S.

<120> DETECTION AND TREATMENT OF PATHOLOGIES LINKED TO FGFR3.

20 <130> 59743-1143

<140> PCT/EP00/04591

<141> 2000-05-04

25 <150> US 60/132,705

<151> 1999-05-05

<160> 20

30 <170> PatentIn Ver. 2.1

<210> 1

<211> 2427

<212> ADN

35 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Wild Type FGFR3-IIIb:

40 <400> 1

45

50

55

EP 1 208 231 B1

atggggcggc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcggc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 5 tgtccccgcg ccgggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 10 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
 aaccccactc cctccatctc ctggctgaag aacggcaggg agttccgcgg cgagcaccgc 600
 attggaggca tcaagctgcg gcatcagcag tggagcctgg tcatggaaag cgtggtgccc 660
 15 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccc a tctgcaggc ggggctgccc 780
 gccaacccaga cggcgggtgct gggcagcgcac gtggagtcc actgcaagg gtacagtgc 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccg 900
 20 gacggcacac cctacgttac cgtgctcaag tcttgatca gtgagagtgt ggaggccgac 960
 gtgcgcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcagacc 1020
 accaaattca taggcgtggc cgaagaaggc ttttggctga gcgtccacgg gccccagca 1080
 25 gccgagggag agctggctga ggcctgacgag gcgggcaagt tctatgcaag catcctcagc 1140

tacggggtgg gcttcttctt gttcattcctg gtgggtggcg ctgtgacgct ctgccgcctg 1200
 30 cgcagcccc ccaagaaag cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcgcac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 cgcatacga ggtgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
 35 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaaagc ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggcgcctg cacgcagggc gggcccctgt acgtgctggg ggagtacgcg 1680
 40 gccaaaggta acctgcggga gtttctgcgg gcgcggcggc ccccgggccc ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctggg gtccctgtgcc 1800
 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcatcca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 45 gcccgggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccggtg 1980
 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tctgctctg ggagatcttc acgctggggg gctccccgta ccccggcatc 2100
 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
 50 tgcacacacg acctgtacat gatcatgcgg gagtgtggtc atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggg ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgcc cccggcccga 2400
 55 cccagcagtg ggggctcgcg gacgtga 2427

EP 1 208 231 B1

<210> 2
<211> 2427
<212> ADN
<213> Artificial Sequence

5

<220>
<223> Description of Artificial sequence: Mutant R248C FGFR3-IIIb:

10

<400> 2

15

20

25

30

35

40

45

50

55

```
atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggcgc tggccatcgt ggccggcgcc 60
tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
ccagagcccg gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
tgtccccgcg ccgggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
cacgaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
ttcagtgtgc gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
gctgaggaca caggtgtgga cacaggggccc cttactgga cacggcccga gcggatggac 480
aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
aaccocactc cctccatctc ctggctgaag aacggcaggg agttccgchg cgagcaccgc 600
attggaggca tcaagctgch gcatacagag tggagcctgg tcatggaaaag cgtggtgccc 660
tcggaccgch gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagach 720
tacaogctgg acgtgctgga gtgctccccg caccggccca tcccgcagge ggggctgccc 780
gccaaccaga cggcggcgcc gggcagcgcac gtcgagttcc accgcaaggc gtacagcgac 840
```

EP 1 208 231 B1

gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccc 900
gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
5 gtgcgctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcagacc 1020
accaatttca taggcgtggc cgagaaggcc ttttggtga gcgttcacgg gccccgagca 1080
gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc 1140
tacggggtgg gcttcctccc gttcacctcg gtgggtggcgg ctgtgacgct ctgccgectg 1200
10 cgcagccccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccc 1260
ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
cgcatcgcaa ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
ctgcctgccg accccaaatg ggagctgtct cgggccccgc tgaccctggg caagcccctt 1440
15 ggggagggct gcttcggcca ggtggteatg gcggagggca tcggcattga caaggaccgg 1500
gccgccaaag ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
atcaacctgc tgggcgctg cacgcagggc gggccccctg acgtgctggt ggagtacgag 1680
20 gccaaaggta acctgcgga gtttctcgg gcgcggcggc ccccgggctt ggactactcc 1740
ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctggt gtcctgtgct 1800
taccaggtgg cccggggcat ggagtacttg gctcccaga agtgcacca cagggacctg 1860
gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
25 gccgggagc tgacacaacct cgactactac aagaagacaa ccaacggccg gctgccccgt 1980
aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
tcctttgggg tcctgctctg ggagatctc acgctggggg gctccccgta ccccggcatc 2100
cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
30 tgcacacacg acctgtacat gatcatgcgg gagtgtggc atgccgcgcc ctcccagagg 2220
cccacctca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgct cccggcccca 2400
35 cccagcagtg ggggctcgcg gacgtga 2427

<210> 3
<211> 2427
40 <212> ADN
<213> Artificial Sequence

<220>
45 <223> Description of Artificial Sequence: Mutant S249C PGFR3-IIIb:

<400> 3

50

55

EP 1 208 231 B1

atggggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 tcctcggagt ccttgggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 5 tgtccccgc cggggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctgggggg cccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 10 ttcagtgtc gggtagacaga cgtccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggcc cttactgga cacgccccga gcggatggac 480
 aaqaagctgc tggccgtgccc ggcggcacaac accgtccgct tccgctgccc agccgctggc 540

aacccccactc cctccatctc ctggctgaag aacggcaggg agtcccgcgg cgagcaccgc 600
 attggaggca tcaagctgcg gcacagcag tggagcctgg tcatggaaag cgtggtgccc 660
 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 20 tacacgctgg acgtgctgga gcgctgccc caccggccca tcctgcaggc ggggctgccc 780
 gccaacccaga cggcgggtgct gggcagcag gtggagttcc actgcaagggt gtacagtgac 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccc 900
 25 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 gtgctcctcc gcctggccaa tctgtcggag cgggacgggg gcgagtaacct ctgtcagacc 1020
 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc 1140
 30 tacgggggtg gcttcttctt gttcatcctg gtggtggcgg ctgtgacgct ctgccgectg 1200
 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcgac aggtgtccct ggagtcaca gcgtccatga gctccaacac accactggtg 1320
 cgcacgcaa ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 35 ctgcctgccc accccaaatg ggagctgtct cgggccccggc tgaccctggg caagccccctt 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaaag ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 40 atcaacctgc tgggcgctg cacgcagggc gggccccctgt acgtgctggt ggagtacgcg 1680
 gccaaaggta acctgcggga gtttctgctg gcgcgcgggc ccccgggccc ggactactcc 1740
 ttegacacct gcaagccgcc cgaggagcag ctcaccttca aggacctggt gtcctgtgcc 1800
 taccaggtgg cccggggcat ggagtaactg gectcccaga agtgcatcca cagggacctg 1860
 45 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 gccggggacg tgcacaacct cgactactac aagaagaaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tctgtctctg ggagatcttc acgtggggg gctccccgta ccccgccatc 2100
 50 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggaaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgctg gactgctggc atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 55 agctccagct cctcagggga cgaactccgtg tttgcccacg acctgctgcc cccggcccca 2400
 cccagcagtg ggggctcgcg gacgtga 2427

EP 1 208 231 B1

<210> 4
<211> 2427
<212> ADN
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence:Mutant G372C FGFR3-IIIb:

<400> 4

10

atggggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
tcctcggagt cctcggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
ccagagcccg gccagcaggga gcagctggtc ttcggcagcg gggatgctgt ggagctgagc 180
tgtccccccg ccggggggtgg tcccactgggg cccactgtct gggtcaggga tggcacaggc 240

15

20

25

30

35

40

45

50

55

EP 1 208 231 B1

ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact cgggggacct cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 5 ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaaacacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacagggggc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
 aaccccactc cctcccatctc ctggetgaag aacggcaggg agttccgcgg cgagcaccgc 600
 10 attggaggca tcaagctgcg gcatacagcag tggagcctgg tcatggaaag cgtggtgccc 660
 tcggaccgcg gcaactacac ctgctcctg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccc 780
 gccaaaccaga cggcgggtgct gggcagcgac gtggagtcc actgcaagg- gtacagtgac 840
 15 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccg 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 gtgctcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 20 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 gccgaggagg agctgggtgga ggctgacgag gcgtgcagtg tgtatgcagg catcctcagc 1140
 tacgggggtg gcttcttctt gttcatcctg gtggtggcgg ctgtgacgct ctgccgcctg 1200
 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 25 cgcatacga ggtgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 ctgcctgccc accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccccaagc ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 30 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggcgctg cacgcagggc gggcccctgt acgtgctggt ggagtacgcg 1680
 gccaaaggta acctgcggga gtttctgctg gcgcggcggc ccccgggccc ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctggt gtcctgtgcc 1800
 35 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcatcca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 gcccgggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccctg 1980
 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 40 tcctttgggg tcctgctctg ggagatcttc acgtggggg gctccccgta ccccgccatc 2100
 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgctg gactgctggc atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 45 gactacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgccacg acctgctgcc cccggcccca 2400
 cccagcagtg ggggctcgcg gacgtga 2427

50 <210> 5
 <211> 2427
 <212> ADN
 <213> Artificial Sequence

55 <220>
 <223> Description of Artificial Sequence: Mutant K652E FGFR3-IIIb:

EP 1 208 231 B1

<400> 5

atggggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 5 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtccccggc 120
 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 tgtccccgc cggggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggctgt gaatgcctcc 300
 10 cacgaggact cggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccg gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgcc agccgctggc 540
 15 aacccccactc cctccatctc ctggctgaag aacggcaggg agttccgcg cgagcaccgc 600
 attggaggca tcaagctgcg gcatacagcag tggagcctgg tcatggaaag cgtggtgcc 660
 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggcca tctgcaggc ggggctgccg 780
 20 gccaaccaga cggcgggtgt gggcagcgcac gtggagtcc actgcaagggt gtacagtgac 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggccc 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 gtgcgcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 25 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc 1140
 tacgggggtg gettcttctt gttcactctg gtggtggcgg ctgtgacgct ctgccgctg 1200
 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttccc 1260
 30 ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 cgcatacga ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 35 gccgccaagc ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggcgctg cacgcagggc gggcccctgt acgtgctggt ggagtacgcg 1680
 gccaaaggtg acctgcggga gtttctgctg gcgcgcgggc ccccgggcct ggactactcc 1740
 40 ttcgacacct gcaagcgcgc cgaggagcag ctcaccttca aggacctggt gtccctgtgcc 1800
 taccaggtg cccggggcat ggagtacttg gcctcccaga agtgcatacca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 gcccgggacg tgcacaacct cgactactac aaggagacaa ccaacggccg gctgcccgtg 1980
 45 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccgccatc 2100
 cctgtggagg agctcttcaa gctgctgaag gaggggcacc gcatggacaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgctg gagtgtctgg atgccgcgcc ctcccagagg 2220
 50 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgccacg acctgctgcc cccggcccca 2400
 cccagcagtg ggggctcgcg gacgtga 2427

55

<210> 6

<211> 2427

EP 1 208 231 B1

<212> ADN

<213> Artificial Sequence

<220>

5 <223> Description of Artificial Sequence:Mutant S373C FGFR3-IIIb:

<400> 6

10

15

20

25

30

35

40

45

50

55

EP 1 208 231 B1

atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 5 ccagagcccg gccagcagga gcagtgtggtc ttcggcagcg gggatgctgt ggagctgagc 180
 tgtccccgc ccgggggtgg tcccatgggg cccactgtct gggccaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact ccggggccta cagctgccgg cagcggctca cgcajcgcgt actgtgccac 360
 10 ttcagtgtgc gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca cagggtgtga cacagggggc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgcc agccgctggc 540
 aacccactc cctccatctc ctggctgaag aacggcaggg agttccgcg cgagcaccgc 600
 15 attggaggca tcaagctgcg gcatcagcag tggagcctgg tcatggaaag cgtggtgcc 660
 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccg 780
 gccaacccaga cggcggtgct gggcagcgc gtggagttcc actgcaaggt gtacaagtac 840
 20 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccg 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 gtgcgcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 25 gccgaggagg agctggtgga ggctgacgag gcgggctgtg tgtatgcagg catcctcagc 1140
 tacggggtgg gcttcttccct gtctcatcctg gtggtggcgg ctgtgacgct ctgccgcctg 1200
 cgcagcccc ccaagaaag cctgggctcc ccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 30 cgcatcgcaa ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 ctgcctgceg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaagc ctgtcacctg agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 35 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggcgcctg cacgcagggc gggcccctgt acgtgctggt ggagtacgcg 1680
 gccaaaggta acctgcggga gtttctgcgg gcgcggcggc ccccgggcct ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcaccttca aggacctggt gtectgtgcc 1800
 40 taccaggtgg cccggggcat ggagtaactg gcctcccaga agtgcaccca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 gcccgggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 45 tcctttgggg tcctgtctctg ggagatcttc acgctggggg gctccccgta ccccggcatc 2100
 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgcgg gagtgtggc atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 50 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgcc cccggcccca 2400
 cccagcagtg ggggctcgcg gacgtga 2427

55 <210> 7
 <211> 2427
 <212> ADN
 <213> Artificial Sequence

EP 1 208 231 B1

<220>

<223> Description of Artificial Sequence: Mutant Y375C FGFR3-IIIb:

<400> 7

5

```

atgggagccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
tgteccccgc ccgggggtgg tcccatgggg cccactgtct gggcaagga tggcacaggg 240
ctggtgccct cggagcgtgt cctggtgggg cccagcggc tgcaggtgct gaatgcctcc 300
cacgaggact ccggggccta cagctgcggg cagcggctca cgcagcgcgt actgtgccac 360
ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
gctgaggaca caggtgtgga cacagggggc ccttactgga cacggcccga gcggatggac 480
aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgcc agccgctggc 540
aaccacctc cctccatctc ctggctgaag aacggcaggg agtcccgcgg cgagcaccgc 600
attggaggca tcaagctgcg gcacagcag tggagcctgg tcatggaaag cgtggtgcc 660
tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccg 780
gccaaccaga cggcggtgct gggcagcgac gtggagtcc actgcaaggt gtacagtgac 840
gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccg 900
gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
gtgcgcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtgtgcagg catcctcagc 1140
tacggggtgg gcttcttctt gttcatcctg gtggtggcgg ctgtgacgct ctgccgcctg 1200
cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
ctcaagcgac aggtgtccct ggagtccaac gcgtccatga getccaacac accactgggtg 1320
cgcatcgcaa ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
gccgccaagc ctgtcacctg agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
atcaacctgc tgggcgcctg cacgcagggc gggcccctgt acgtgctggt ggagtacgcg 1680
gccaagggta acctgcggga gtttctgcgg gcgcggcggc ccccgggctt ggactactcc 1740
ttcgacacct gcaagccgcc cgaggagcag ctcaccttca aggacctggt gtcctgtgcc 1800
taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcattca cagggacctg 1860
gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
gccggggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccggcatc 2100
cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
tgcacacacg acctgtacat gatcatgccc gagtgcctggc atgccgcgcc ctcccagag 2220

```

55

EP 1 208 231 B1

cccaccttca agcagctggc ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
5 agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgcc cccggcecca 2400
cccagcagtg ggggctcgcg gacgtga 2427

10 <210> 8
<211> 2427
<212> ADN
<213> Artificial Sequence

15 <220>
<223> Description of Artificial Sequence:Mutant K652M FGFR3-IIIb:

<400> 8

20

25

30

35

40

45

50

55

EP 1 208 231 B1

atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 5 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 tgtccccgc cggggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact cgggggacct cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 10 ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgcc agccgctggc 540
 aacccccactc cctccatctc ctggctgaag aacggcaggg agttccgcg cgagcaccgc 600
 15 attggaggca tcaagctgcg gcatcagcag tggagcctgj tcatggaaag cgtggtgcc 660
 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccg 780
 gccaaccaga cggcgggtgt gggcagcgcac gtggagtcc actgcaaggt gtacagtgcac 840
 20 gcacagcccc acatccagtg gctcaagcac gtggaggatga acggcagcaa ggtgggcccc 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 gtgcgcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 25 gccgaggagg agctgggtga ggtgacgag gcgggacgtg tgtatgcagg catcctcagc 1140
 tacggggtgg gcttcttctt gttcatcctg gtggtggcgg ctgtgacgct ctgccgectg 1200
 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 30 cgcacgcaa ggctgtctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 ctgctgccc accccaaatg ggagctgtct cgggcccggc tgaccctggg caagccccctt 1440
 ggggagggct gcttcggcca ggtggatcat gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaagc ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 35 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggcgectg cacgcagggc gggcccctgt acgtgctggt ggagtacgcg 1680
 gccaaaggta acctgcggga gttctctcgg gcgcgcgcc ccccgggect ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctggt gtcctgtgcc 1800
 40 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcacca cagggacctg 1860
 gctgccccga atgtgctggc gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920

45 gcccgggacg tgcacaacct cgactactac aagatgacaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccggcatc 2100
 50 cctgtggagg agctcttcaa gctgctgaag gagggcacc gcattggaaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgcgg gagtgtctgg atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcagc cagtactccc cgggtggcca ggacaccccc 2340
 55 agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgcc cccggccccca 2400
 cccagcagtg ggggctcgcg gacgtga 2427

EP 1 208 231 B1

<210> 9
 <211> 2427
 <212> ADN
 <213> Artificial Sequence

5

<220>
 <223> Description of Artificial Sequence:Mutant X809C FGFR3-IIIb:

<400> 9

10

```

atggggcggc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
ccagagcccg gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
15 tgtcccccgc cggggggtgg tcccatgggg cccactgtct gggcaagga tggcacaggg 240
ctggtgcccct cggagcgtgt cctggtgggg cccagcggc tgcaggtgct gaatgcctcc 300
cacgaggact cgggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
20 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
aaccctactc cctccatctc ctggctgaag aacggcaggg agttccgcgg cgagcaccgc 600
attggaggca tcaagctgcg gcatcagcag tggagcctgg tcatggaaag cgtggtgccc 660
25 tcggaccgcy gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
tacacgctgg acgtgctgga gcgctccccg caccggccca tectgcaggc ggggctgccc 780
gccaaccaga cggcgggtgct gggcagcgcac gtggagtcc actgcaaggt gtacagtgac 840
gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccg 900
30 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
gtgcgccctc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
accaatttca taggcgtggc cgagaaggcc ttttggtga gcgttcacgg gccccgagca 1080
gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc 1140
35 tacggggtgg gcttcttctt gttcatcctg gtggtggcgg ctgtgacgct ctgccgcctg 1200
cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactgggtg 1320
cgcacgcgaa ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
40 ctgcctgccc accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
gccgccaagc ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
45 ctgtcggacc tgggtgtctga gatgagatg atgaagatga tcgggaaaca caaaaacatc 1620

```

45

50

55

EP 1 208 231 B1

atcaacctgc tgggagcctg cacgcagggc gggcccctgt acgtgctggg ggagtacgcg 1680
 gccaaaggta acctgcggga gtctctgcgg gcgcggcggc ccccgggctt ggactactcc 1740
 5 ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctggt gtcctgtgcc 1800
 taccaggtag cccggggcat ggagtacttg gcctcccaga agtgcacca cagggacctg 1860
 gctgcccgca atgtgctggg gaccgaggac aacgtgatga agatcgcaga ctccgggctg 1920
 gcccgggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
 10 aagtggatgg cgcctgagge cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccgccatc 2100
 cctgtggagg agctcttcaa gctgctgaag gaggggccacc gcatggacaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgagg gagtgtctggc atgcccggcc ctcccagagg 2220
 15 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcccttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgccacg acctgctgcc cccggcccca 2400
 cccagcagtg ggggctcggc gacgtgc 2427

20

<210> 10

<211> 2427

<212> ADN

25

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Mutant X809G FGFR3-IIIb:

(Mutant 1)

30

<400> 10

atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 35 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 ccagagcccg gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 tgtccccgc cccgggggtg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaaggctt gaatgcctcc 300
 40 cacgaggact cccgggccta cagctgcggg cagcggctca cgcagcgcgt actgtgccac 360
 ttcagtgtgc gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
 45 aaccccactc cctccatctc ctggetgaag aacggcaggg agttccgagg cgagcaccgc 600
 attggaggca tcaagctgcg gcatcagcag tggagcctgg tcatggaaag cgtggtgccc 660
 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat cgggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccc 780
 50 gccaaaccaga cggcgggtgt gggcagcgcg gtggagtcc actgcaagggt gtacagtgac 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtggggccc 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 gtgcgcctcc gectggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 55 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 gccgaggagg agctggctgga ggtctgacgag gcgggcagtg tgatgcagg catcctcagc 1140
 tacggggctg gcttcttccc gctcactctg gctggctggc ctgtgacgct ctgccgctc 1200

EP 1 208 231 B1

5 cgagccccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 cgcatcgcaa ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcatcga caaggaccgg 1500
 gccgccaagc ctgtcaccgt agccgtgaag atgtctgaaag acgatgccac tgacaaggac 1560
 10 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggcgctg cacgcagggc gggcccctgt acgtgctggt ggagtacgag 1680
 gcccaaggta acctgcggga gtttctgagg gcgcggcgcc ccccgggect ggactactcc 1740
 ttgcagacct gcaagccgcc cgaggagcag ctcacctca aggacctggt gtccctgtgcc 1800
 15 taccagggtg cccggggcat ggagtaactg gcctcccaga agtgcattca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgaga cttcgggctg 1920
 gcccgggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 20 tcctttgggg tcctgctctg ggagatcttc acgtggggg gctccccgta ccccggcac 2100
 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgcgg gagtgtgctg atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 25 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgccacg acctgctgcc cccggcccca 2400
 cccagcagtg ggggctcgcg gacggga 2427

30
 <210> 11
 <211> 2427
 <212> ADN
 <213> Artificial Sequence

35
 <220>
 <223> Description of Artificial Sequence: Mutant X809G FGFR3-IIIb:
 (Mutant 2)

40
 <400> 11

45

50

55

EP 1 208 231 B1

atggggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 5 tgtcccccgcc cggggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgcctt cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
 cagcaggact cgggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 10 ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgcc agccgctggc 540
 aacccaactc cctccatctc ctggctgaag aacggcaggg agttccgagg cgagcaccgc 600
 15 attggaggca tcaagctgcg gcatcagcag tggagcctgg tcatggaaag cgtggtgccc 660
 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctcg acgtgctgga gcgctccccg caccggccca tccctcaggg ggggctgccc 780

 20
 gccaaccaga cggcgggtgc gggcagcgc gtcgagttcc actgcaaggt gtacagtgc 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccc 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 25 gtgcgcctcc gectggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcagacc 1020
 accaatcca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc 1140
 tacggggtgg gcttcttctt gttcatcctg gtgggtggcg ctgtgacgct ctgccgctg 1200
 30 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttccc 1260
 ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 cgcacgcgaa ggctgtcctc aggggagggc cccacgctgg ccaatgctc cgagctcgag 1380
 ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgacctggg caagcccc 1440
 35 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaagc ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggcgctg cacgcagggc gggcccctgt acgtgctggg ggagtacgcg 1680
 40 gccaaaggta acctgcggga gtttctgcgg gcgcggcggc ccccggcct ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctaccttca aggacctggg gtccctgtgc 1800
 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcatcca cagggacctg 1860
 gctgcccgca atgtgctggg gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 45 gcccgggacg tgcaaacct cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgctgagggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgtggggg gctccccgta ccccgcatc 2100
 cctgtggagg agctcttcaa gctgctgaag gaggggcacc gcatggaaa gcccgccaac 2160
 50 tgcacacacg acctgtacat gatcatgcgg gagtgtggtc atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggg ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgcc cccggcccca 2400
 55 cccagcagtg ggggctcgcg gacgaga 2427

EP 1 208 231 B1

<210> 12
<211> 2427
<212> ADN
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence:Mutant X809G FGFR3-IIIb:
(Mutant 3)

10

<400> 12

atggggcgccc ctgcctgccc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
15 ccagagcccc gccagcagga gcagttggtc ttccggcagcg gggatgctgt ggagctgagc 180
tgtccccccg ccgggggtgg tcccatgggg cccactgtct gggccaagga tggcacaggg 240
ctgggtgccct cggagcgtgt cctgggtgggg cccagcgggc tgcaggtgct gaatgcctcc 300
caccagggact ccggggccca cagctgcccg cagcggctca cggagcggct actgtgccac 360

20

25

30

35

40

45

50

55

EP 1 208 231 B1

5 ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
 aacccccactc cctccatctc ctggctgaag aacggcaggg agttccgagg cgagcaccgc 600
 attggaggca tcaagctgcg gcatcagcag tggagcctgg tcatggaaag cgtgggtgccc 660
 10 tcggaccgcg gcaactacac ctgctcctg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccca tccctgcaggc ggggctgccc 780
 gccaacccaga cggcgggtgct gggcagcgac gtggagtctc actgcaaggt gtacagtgc 840
 gcacagcccc acatccagtg gctcaagcac gtcggaggtga acggcagcaa ggtgggcccc 900
 15 gacggcacac cctacgttac cgtgctcaag tccctggatca gtgagagtgt ggaggccgac 960
 gtgctcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 accaatttca taggcgtggc cgagaaggcc ttttggtgta gcgttcacgg gccccgagca 1080
 gccgaggagg agctgggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc 1140
 20 tacgggggtg gcttcttctc gttcatcctg gtcggtggcgg ctgtgacgct ctgccgctg 1200
 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccc 1260
 ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 cgcacgcgaa ggetgtctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 25 ctgcctgccc accccaaatg ggagctgtct cgggccccgg tgaccctggg caagccccct 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaaag ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggagcctg cacgcagggc gggcccctgt acgtgctggt ggagtacgcg 1680
 30 gccaaaggtg acctgcggga gtttctgctg gcgcggcggc ccccgggctt ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctggt gtcctgtgcc 1800
 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcacca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 35 gccgggagc tgcaacaact cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgctgaggg cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tccctgctctg ggagatcttc acgctggggg gctccccgta ccccggcatc 2100
 cctgtggagg agctcttcaa gctgctgaag gaggggccacc gcatggacaa gcccgccaac 2160
 40 tgacacacag acctgtacat gatcatgctg gagtgtctgg atgccgctcc ctcccagagg 2220
 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtcccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgcc cccggcccca 2400
 45 cccagcagtg ggggctcgcg gacgcga 2427

<210> 13

<211> 2427

50 <212> ADN

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Mutant X809L FGFR3-IIIb:

55

<400> 13

EP 1 208 231 B1

atgsgcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggcggggccc 60

5
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 tgtccccgc ccgggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 10 ctggtgccct cggagcgtgt cctgggtggg ccccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact ccggggccta cagctgcccg cagcggctca cgcagcgcgt actgtgccac 360
 ttcagtgtgc gggtgacaga cgtccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacagggggc cttactgga cacggcccga gcggatggac 480
 15 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgcc agccgctggc 540
 aacccactc cctccatctc ctggctgaag aacggcaggg agtcccgcg cgagcaccgc 600
 attggaggca tcaagctgcg gcacagcag tggagcctgg tcatggaaag cgtggcgccc 660
 tcggaccgcy gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 20 tacacgctgg acgtgctgga gcgctcccc caccggccca tccctgcaggc ggggctgccg 780
 gccaacaga cggcgggtgc gggcagcagc gtggagttcc actgcaaggt gtacagtgac 840
 gcacagcccc acatccagtg gctcaagcac gtggaggatga acggcagcaa ggtgggcccc 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 25 gtgcgcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 accaatttca taggcgtggc cgagaaggcc ttttggtga gcgttcacgg gccccgagca 1080
 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg cactctcagc 1140
 tacggggtgg gcttcttccct gttcactctg gtggtggcgg ctgtgacgct ctgccgcctg 1200
 30 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcagc aggtgtccct ggagtccaac gcgtccatga gctccaacac accactgggtg 1320
 cgcacgcgaa ggetgtctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
 35 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaaag ctgtcacctg agccgtgaag atgctyaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggcgcctg cacgcagggc gggcccctgt acgtgctggt ggagtacgcy 1680
 40 gccaaaggta acctgcggga gttctgcgg gcgcggcgcc ccccgggctt ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctgt gtctgtgcc 1800
 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcaccca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 45 gccgggagc tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgtggggg gctcccctga ccccggcctc 2100
 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
 50 tgcacacacg acctgtacat gatcatgcgg gagtgtggc atgcccgcc ctcccagagg 2220
 cccacctca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgcccaag acctgctgcc cccggcccca 2400
 55 cccagcagtg ggggctcgcg gacgtta 2427

EP 1 208 231 B1

<210> 14
<211> 2427
<212> ADN
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence:Mutant N542K FGFR3-IIIb:
(Mutant 1)

10

<400> 14

15

20

25

30

35

40

45

50

55

EP 1 208 231 B1

atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtccccggc 120
 5 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 tgtccccgc ccgggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctggtgggg cccagcggc tgcaggtgct gaatgcctcc 300
 caccagggact ccggggccta cagctgcccg cagcggctca cgcagcgcgt actgtgccac 360
 10 ttcagtgtgc gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacagggggc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
 aacccactc cctccatctc ctggctgaag aacggcaggg agttccgcg cgagcaccgc 600
 15 attggaggca tcaagctgcy gcatcagcag tggagcctgg tcatggaaag cgtggtgcc 660
 tcggaccgcy gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccc 780
 gccaacccaga cggcgggtgct gggcagcgcac gtggagttcc actgcaagggt gtacagtgc 840
 20 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggccc 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 gtgcgectcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 25 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc 1140
 tacggggtgg gcttcttccct gttcatcctg gtggtggcgg ctgtgacgct ctgccgcctg 1200
 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttccc 1260
 ctcaagcgac aggtgtccct ggagtcacac gcgtccatga gctccaacac accactggtg 1320
 30 cgcacgcaa ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaaac ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 35 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaaaactgc tgggcgctc cagcagggc gggcccctgt acgtgctggt ggagtacgcy 1680
 gccaaaggta acctgcggga gtttctgcyg gcgcggcggc ccccgggcct ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctggt gtcctgtgcc 1800
 40 taccaggtgg cccggggcat ggagtaactg gcctcccaga agtgcaccca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgaga cttcgggctg 1920
 gcccgggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 45 tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccggcac 2100
 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgcyg gagtgtgcyg atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 50 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgccacg acctgctgcc cccggcccca 2400
 cccagcagtg ggggctcgcg gacgtga 2427

55
 <210> 15
 <211> 2427
 <212> ADN

EP 1 208 231 B1

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Mutant N542K FGFR3-IIIb:

(Mutant 2)

<400> 15

10 atggggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagecgcaga agtcccgggc 120
 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 tgtcccccg cggggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 15 ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 ttcagtgtgc gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggccc cttactgga cacggcccga gcggatggac 480
 20 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
 aacccccactc cctccatctc ctggetgaag aacggcaggg agttccgcgg cgagcaccgc 600
 attggaggca tcaagctgcg gcatacagcag tggagcctgg tcatggaaag cgtggtgccc 660
 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 25 tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccg 780
 gccaaaccaga cggcgggtgct gggcagcgcac gtggagtacc actgcaaggt gtacagtgac 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggccccg 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 30 gtgcgectcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcage 1140
 tacggggtgg gcttcttctc gtcatcctg gtggtggcgg ctgtgacgct ctgccgctg 1200
 35 cgcagcccc ccaagaaagg cctgggetcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcgac aggtgtcccc ggagtcacac gcgtccatga gctccaacac accactggtg 1320
 cgcatacga ggtgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 ctgcctgccg accccaaatg ggagctgtct cgggccccgc tgaccctggg caagccccct 1440
 40 ggggagggt gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaagc ctgtcacctg agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaagctgc tgggcgctg caecgagggc gggcccctgt acgtgctggt ggagtacgcg 1680
 45 gccaaaggta acctgcggga gtttctgcgg gcgcggcggc ccccgggccc ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctggt gtectgtgcc 1800
 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcacca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 50 gcccgggacg tgcacaacct cgactactac aagaagaaa ccaacggccg gctgcccgtg 1980
 aagtggatgy cgcttgaggc cttgtttgac cgagtctaca ctaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccgccatc 2100

55

EP 1 208 231 B1

5 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
tgcacacacg acctgtacat gatcatgcgg gagtgctggc atgccgcgcc ctcccagagg 2220
cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
10 agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgcc cccggcccca 2400
cccagcagtg ggggctcgcg gacgtga 2427

15 <210> 16
<211> 2427
<212> ADN
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: Mutant G382R FGFR3-IIIb:
(Mutant 1)

<400> 16

25

30

35

40

45

50

55

EP 1 208 231 B1

atgggagccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtccccggc 120
 5 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 tgtccccgc ccgggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 10 ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgcc agccgctggc 540
 aacccactc cctccatctc ctggctgaag aacggcaggg agttccgagg cgagcaccgc 600
 attggaggca tcaagctgcg gcatacagcag tggagcctgg tcatggaaag cgtggtgcc 660
 15 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccca tccctgcaggc ggggctgccg 780
 gccaacccaga cggcgggtgct gggcagcgcac gtggagtcc actgcaagggt gtacagtgcac 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccc 900
 20 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 gtgcgcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc 1140
 25 tacagggtgg gcttcttccct gttcatcctg gtggtggcgg ctgtgacgct ctgccgcctg 1200
 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 cgcatacga ggtgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 30 ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagccccct 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaaag ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 35 atcaacctgc tgggcgcctg cacgcagggc gggcccctgt acgtgctggt ggagcagcgc 1680

gccaaaggta acctgcggga gtttctgcgg gcgcggcggc ccccgggccc ggactactcc 1740
 40 ttcgacacct gcaagccgcc cgaggagcag ctacacttea aggacctggt gtcctgtgcc 1800
 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcatcca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgca ca ttcgggctg 1920
 45 gcccgggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccggtg 1980
 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccggcaatc 2100
 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcattgacaa gcccgccaac 2160
 50 tgcacacacg acctgtacat gatcatgagg gaggctggc atgccgcgcc ctcccagagg 2220
 cccaccttea agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactcctg tttgcccacg acctgctgcc cccggcccca 2400
 55 cccagcagtg ggggctcgcg gacgtga 2427

<210> 17

EP 1 208 231 B1

<211> 2427
<212> ADN
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence:Mutant G382R FGFR3-IIIb:
(Mutant 2)

10 <400> 17

atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
15 ccagagcccg gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
tgtcccccgc ccgggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
cacgaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
20 ttcagtgtgc ggggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgcc agccgctggc 540
aaccaccctc cctccatctc ctggtgaag aacggcaggg agttccgcgg cgagcaccgc 600
25 attggaggea tcaagctgcg gcatcagcag tggagcctgg tcatggaaag cgtggtgcc 660
tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccg 780
gccaaccaga cggcgggtgct gggcagcgc acgtggagttcc actgcaagggt gtacagtgac 840
30 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccg 900
gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
gtgcgcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcgagcc 1020
accaatttca taggcgtggc cgagaaggcc ttttggtgta gcgttcacgg gccccgagca 1080
35 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc 1140
taccgggtgg gcttcttccct gttcatcctg gtggtggcgg ctgtgacgct ctgccgcctg 1200
cgcagccccc ccaagaaag cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260

40

45

50

55

EP 1 208 231 B1

ctcaagcgac aggtgtcccc ggagtccaac gcgtccatga gctccaacac accactygtg 1320
 cgcatcgcaa ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 5 ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaagc ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 10 atcaacctgc tgggcgcctg cacgcagggc gggcccctgt acgtgctggg ggagtacgag 1680
 gccaaaggta acctgcggga gtttctgcgg gcgcggcggc ccccgggcct ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcaccttca aggacctggg gtcctgtgcc 1800
 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcatcca cagggacctg 1860
 15 gctgcccgca atgtgctggg gaccgagga aacgtgatga agatcgaga cttcgggctg 1920
 gcccgggacg tgcacaacct cgactacta aagaagacaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgctgaggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccggcatc 2100
 20 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgcgg gagtgtctggc atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggg ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 25 agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgcc cccggcccca 2400
 cccagcagtg ggggctcgcg gacgtga 2427

30 <210> 18
 <211> 2427
 <212> ADN
 <213> Artificial Sequence

35 <220>
 <223> Description of Artificial Sequence: Mutant G377C FGFR3-IIIb:

<400> 18

40

45

50

55

EP 1 208 231 B1

atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 ccagagcccc gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
 5 tgtccccgcg ccgggggtgg tcccatgggg cccactgtct gggcaagga tggcacaggg 240
 ctggtgccct cggagcgtgt cctggtgggg cccagcggc tgcaggtgct gaatgcctcc 300
 cacgaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
 10 ttcagtgtgc gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggcc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgcc agccgctggc 540
 aaccccactc cctccatctc ctggtgaag aacggcaggg agttccgcgg cgagcaccgc 600
 15 attggaggca tcaagctgcg gcacagcag tggagcctgg tcatggaaag cgtggtgcc 660
 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccg 780
 gccaaccaga cggcgggtgct gggcagcgc gtggagtcc actgcaaggt gtacagtgc 840
 20 gcacagcccc acatccagtg gctcaagcac gtcggaggtga acggcagcaa ggtgggcccg 900
 gacggcaccac cctacgttac cgtgctcaag tcctggatca gtcgagctgc ggagccgcac 960

 25 gtgcgcctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcagacc 1020
 accaatttca taggcgtggc cgagaaggcc ttttggctga gcgttcacgg gccccgagca 1080
 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgtatgcatg cctcctcagc 1140
 30 tacggggtgg gcttcttccct gttcatcctg gtggtggcgg ctgtgacgct ctgccgcctg 1200
 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcgc acggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 cgcacgcaa ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag 1380
 35 ctgcctgccg accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 gccgccaagc ctgtcacctg agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 40 atcaacctgc tgggcgcctg cacgcagggc gggcccctgt acgtgctggt ggagtacgcg 1680
 gccaagggtg acctgcggga gttctcgcgg gcgcggcggc ccccgggctt ggactactcc 1740
 ttcgacacct gcaagccgcc cgaggagcag ctcaccttca aggacctggt gtcctgtgcc 1800
 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcaccca cagggacctg 1860
 45 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgaga cttcgggctg 1920
 gccggggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccgccatc 2100
 50 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggaaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgcgg gagtgtggc atgccgcgcc ctcccagagg 2220
 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 55 agctccagct cctcagggga cgactccgtg tttgcccacg acctgctgcc cccggcccca 2400
 cccagcagtg ggggctcgcg gacgtga 2427

EP 1 208 231 B1

<210> 19
<211> 2427
<212> ADN
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence:Mutant A393E FGFR3-IIIb:

<400> 19

10

```
atggggcggc ctgcctggcg cctcgcgctc tgcgtggccg tggccatcgt ggccggcgcc 60
tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
ccagagcccg gccagcagga gcagttggtc ttcggcagcg gggatgctgt ggagctgagc 180
tgtccccgc ccgggggtgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
ctggtgccct cggagcgtgt cctggtgggg ccccagcggc tgcaggtgct gaatgcctcc 300
cacgaggact ccggggccta cagctgccgg cagcggctca cgcagcgcgt actgtgccac 360
ttcagtgtgc gggtgacaga cgctccatcc tcgggagatg acgaagacgg ggaggacgag 420
gctgaggaca caggtgtgga cacagggggc ccttactgga cacggcccga gcggatggac 480
aagaagctgc tggccgtgcc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
aaccaccact cctccatctc ctggctgaag aacggcaggg agttccgcgg cgagcaccgc 600
attggaggca tcaagctgcs gcatccagcag tggagcctgg tcaatggaaa cgtggctgccc 660
```

30

35

40

45

50

55

EP 1 208 231 B1

tcggaccgcg gcaactacac ctgcgctcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg caccggccca tcctgcaggc ggggctgccg 780
 5 gccaaccaaga cggcgggtgct gggcagcgac gtggagttcc actgcaaggt gtacagtgac 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggcagcaa ggtgggcccc 900
 gacggcacac cctacgttac cgtgctcaag tcctggatca gtgagagtgt ggaggccgac 960
 gtgcgctcct gcctggccaa tgtgtcggag cgggacgggg gcgagtacct ctgtcagacc 1020
 10 accaatttca taggcgtggc cgagaaggcc tttcggctga gcgtccacgg gccccgagca 1080
 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tgatgcagg catccctcagc 1140
 tacggggctg gctctctcct gctcatcctg gtggctgagc ctgtgacgct ctgccgctcg 1200
 cgcagcccc ccaagaaag cctgggctcc ccaccgtgc acaagatctc ccgcttcccc 1260
 15 ctcaagcgac aggtgtccct ggagtccaac gcgtccatga gctccaacac accactgggtg 1320
 cgcatcgcaa ggctgtcctc aggggagggc ccacgctgg ccaatgtctc cgagctcagc 1380
 ctgcctgccg accccaaatg ggagctgtct cgggccccggc tgaccctggg caagccccct 1440
 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg 1500
 20 gccgccaaag ctgtcacctg agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc 1620
 atcaacctgc tgggcgctg cacgcagggc gggccccctg acgtgctggt ggagtacgcg 1680
 gccaaaggta acctgcggga gtttctgctg gcgcggcggc ccccgggcct ggactactcc 1740
 25 ttcgacacct gcaagccgcc cgaggagcag ctcacctca aggacctggt gtccctgtgcc 1800
 taccaggtgg cccggggcat ggagtacttg gcctcccaga agtgcatcca cagggacctg 1860
 gctgccccga atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 gcccgggacg tgcacaacct cgactactac aagaagacaa ccaacggccg gctgcccgtg 1980
 30 aagtggatgg cgctgagggc cttgtttgac cgagtctaca ctcaccagag tgacgtctgg 2040
 tcctttgggg tcctgctctg ggagatcttc acgtggggg gctccccgta ccccggcac 2100
 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggacaa gcccgccaac 2160
 tgcacacacg acctgtacat gatcatgctg gagtgtggtc atgccgctcc ctcaccagag 2220
 35 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gagtacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactccgtg tttgcccacg acctgtgtcc cccggcccca 2400
 40 cccagcagtg ggggctcgcg gacgtga 2427

<210> 20
 <211> 2427
 45 <212> ADN
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Mutant P250R FGFR3-IIIb:

50 <400> 20

55

EP 1 208 231 B1

atgggagccc ctgcctgcgc cctcgcgctc tgcgtggccg tggccatcgt ggccggcggc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 ccagagcccc gccagcagga gcagtgggtc ttcggcagcg gggatgctgt ggagctgagc 180
 5 tgteccccgc ccgggggtgg tcccatgggg cccactgtct gggccaagga tggcacaggg 240
 ctgggtgccc cggagcgtgt cctgggtggg cccagcggc tgcaggtgct gaatgctcc 300
 cacgaggaact ccgggggcta cagctgcccg cagcggctca cgcaggtgct actgtgccc 360

 10
 tccaagtgtg gggctgaca caagctccatcc tccggagatg acgaaagacgg ggaggaacgag 420
 gctgaggaca caggtgtgga cacagggggc ccttactgga cacggtccga gcggatggac 480
 15 aagaagctgc tggcctgccc ggccggccaac accgtccgct tccgctgccc agccgctggc 540
 aaccccactc cctccatctc ctggctgaag aacggcaggg agtcccgcg cgagcaccgc 600
 attggaggca tcaagctgct gcatcagcag tggagcctgg tcaaggaag cgtgggtccc 660
 tccgaccgcg gcaactacac ctgcgtcctg gagaacaagt tctgtagcat ccggcagacg 720
 20 tacacgctgg acgtgctgga gcgctcccgg caccggccca tccagcaggc ggggctgccc 780
 gccaaccaga cggcgggtgct gggcagcgcac gtggagtctc actgaaaggt gtacagtgac 840
 gcacagcccc acatccagtg gctcaagcac gtggaggtga acggaagca ggtgggcccg 900
 gacggcacac cctacgttac cgtgctcaag tccctggatca gtcagagtgct ggagggcccgac 960
 25 gtgctgctcc gcctggccaa tgtgtcggag cgggacgggg gcgagtaact ctgtcagacc 1020
 accaatttca taggcgtgyc cgagaaggcc ttttggctga gcgtccacgg gccccgagca 1080
 gccgaggagg agctggtgga ggctgacgag gcgggcagtg tctatgacgg catcctcagc 1140
 tacgggggtg gcttcttctt gttcatcctg gtggtggcgg ctgtgacgct ctgcccctg 1200
 30 cgcagcccc ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttcccg 1260
 ctcaagcagc aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg 1320
 cgcacgcaa ggctgtcttc aggggagggc cccacgctgg ccaagtctc cgagctcag 1380
 ctgcctgccc accccaaatg ggagctgtct cgggcccggc tgaccctggg caagccccct 1440
 35 ggggagggct gcttcggcca ggtggtcatg gcggaggcca tggcattga caaggaccgg 1500
 gccgccaagc ctgtcaccgt agccgtgaag atgctgaaag acgatgccac tgacaaggac 1560
 ctgtcggacc tgggtgtctga gatggagatg atgaagatga tccggaaaca caaaaacatc 1620
 atcaacctgc tgggcgctg cacgcagggc gggcccctgt acgtgctggt ggagtacg 1680
 40 gccaaaggta acctgcggga gtttctgctg gcgcgggcgg ccccgggcct ggactactcc 1740
 ttcgacacct gcaagccgccc cgaggagcag ctacacctca aggacctggt gtcctgtgcc 1800
 taccaggtgg cccggggcat ggagtacttg gctcccaga agtgcatcca cagggacctg 1860
 gctgcccgca atgtgctggt gaccgaggac aacgtgatga agatcgcaga cttcgggctg 1920
 gcccgggacg tgcacaacct cgactactac aagaagaaa ccaacggccg gctgcccgtg 1980
 45 aagtggatgg cgcctgaggc cttgtttgac cgagtctaca ctaccagag tgactgtctg 2040
 tcctttgggg tcctgctctg ggagatcttc acgctggggg gctccccgta ccccgccatc 2100
 cctgtggagg agctcttcaa gctgctgaag gagggccacc gcatggaaa gcccggcaac 2160
 tgacacacag acctgtacat gatcatgctg gactgctggc atgcccggcc ctcccagagg 2220
 50 cccaccttca agcagctggt ggaggacctg gaccgtgtcc ttaccgtgac gtccaccgac 2280
 gactacctgg acctgtcggc gcctttcgag cagtactccc cgggtggcca ggacaccccc 2340
 agctccagct cctcagggga cgactcctg tttgcccacg acctgctgccc cccggcccca 2400
 cccagcagtg ggggctcgcg gacgtga 2427

55

Claims

1. A method for detecting carcinomas in a biological sample, comprising identifying FGFR3 mutations.
- 5 2. The method of claim 1, comprising screening for single nucleotide mutation(s) in nucleic acids of the group comprising genomic DNA, RNA or cDNA.
3. The method of claim 1, comprising screening for single mutation(s) in proteins.
- 10 4. The method of claim 1., comprising screening for mutations creating cysteine residues in the extracellular or transmembrane domains of the receptor.
5. The method of claim 1, comprising screening for mutations resulting in at least one amino-acid substitution in the kinase domain of the receptor.
- 15 6. The method of claim 5, comprising screening of activating mutation(s) of FGFR3.
7. The method of claim 6, comprising screening of activating mutation(s) of FGFR3-IIIb.
- 20 8. The method of claim 1, comprising screening for mutation(s) in the group comprising exon 7, encoding the junction between immunoglobulin-like domains II and III of FGFR3, exon 10, encoding the transmembrane domain, exon 15, encoding the tyrosine kinase domain I, and the exon encoding the C-terminal part.
- 25 9. The method of claim 1, comprising screening for missense mutations such as implicated in thanatophoric dysplasia, NSC, achondroplasia, SADDAN, or hypochondroplasia.
- 30 10. The method of claim 9, wherein the mutations comprise R248C, S249C, G372C, S373C, Y375C, K652E, K652M, JB09G, J809C, J809R, J809L, P250R, G377C, G382R, A393E, N542K.
- 30 11. The method of claim 9, comprising screening R248C, S249C, G372C, K652E and Y375C mutations.
12. The method of claim 1, wherein the biological sample is selected in the group comprising a tissue, bone marrow, or a body fluid.
- 35 13. The method of claim 12, wherein said body fluid is selected in the group comprising blood, urine from a warm-blooded animal.
14. The method of claim 13, wherein said body fluid is from a human.
- 40 15. The method of claim 1 for detecting human bladder and cervix carcinomas.
16. The method of claim 1, for detecting lung, breast, colon, skin cancers.
17. Use of an antibody directed against FGFR3 for the manufacture of a medicament for treating carcinomas.
- 45 18. Use according to claim 17 wherein the antibody is monoclonal.
19. Use according to claim 17 wherein the antibody is humanized.
- 50 20. Use of an antisens oligonucleotides directed against a wild type or mutated FGFR3 isoform for the manufacture of a medicament for treating carcinomas.
21. Use according to claims 17 to 20, wherein said carcinomas are cervix or bladder carcinomas.
- 55 22. A transgenic animal excluding human comprising a construction which comprises a keratin promoter and cDNA of mutated FGFR3, allowing the expression of a mutated FGFR3 directed in epithelium.

Patentansprüche

1. Verfahren zum Nachweisen von Karzinomen in einer biologischen Probe, umfassend das Identifizieren von FGFR3-Mutationen.
2. Verfahren gemäß Anspruch 1, umfassend das Suchen nach Einzelnucleotidmutationen in Nucleinsäuren der Gruppe, die genomische DNA, RNA oder cDNA umfasst.
3. Verfahren gemäß Anspruch 1, umfassend das Suchen nach Einzelmutationen in Proteinen.
4. Verfahren gemäß Anspruch 1, umfassend das Suchen nach Mutationen, die Cysteinreste in der extrazellulären Domäne oder der Transmembrandomäne des Rezeptors verursachen.
5. Verfahren gemäß Anspruch 1, umfassend das Suchen nach Mutationen, die zu wenigstens einer Aminosäuresubstitution in der Kinasedomäne des Rezeptors führen.
6. Verfahren gemäß Anspruch 5, umfassend das Suchen nach aktivierenden Mutationen von FGFR3.
7. Verfahren gemäß Anspruch 6, umfassend das Suchen nach aktivierenden Mutationen von FGFR3-IIIb.
8. Verfahren gemäß Anspruch 1, umfassend das Suchen nach Mutationen in der Gruppe, die das Exon 7, das die Verknüpfung zwischen den immunglobulinartigen Domänen II und III von FGFR3 codiert, das Exon 10, das die Transmembrandomäne codiert, das Exon 15, das die TyrosinKinase-Domäne I codiert, und das Exon, das den C-terminalen Teil codiert, umfasst.
9. Verfahren gemäß Anspruch 1, umfassend das Suchen nach Fehlsinnmutationen, wie sie bei thanatophorer Dysplasie, NSC, Achondroplasie, SADDAN oder Hypochondroplasie impliziert sind.
10. Verfahren gemäß Anspruch 9, wobei die Mutationen R248C, S249C, G372C, S373C, Y375C, K652E, K652M, J809G, J809C, J809R, J809L, P250R, G377C, G382R, A393E, N542K umfassen.
11. Verfahren gemäß Anspruch 9, umfassend das Suchen nach den Mutationen R248C, S249C, G372C, K652E und Y375C.
12. Verfahren gemäß Anspruch 1, wobei die biologische Probe aus der Gruppe ausgewählt ist, die ein Gewebe, Knochenmark oder eine Körperflüssigkeit umfasst.
13. Verfahren gemäß Anspruch 12, wobei die Körperflüssigkeit aus der Gruppe ausgewählt ist, die Blut und Urin von einem warmblütigen Tier umfasst.
14. Verfahren gemäß Anspruch 13, wobei die Körperflüssigkeit von einem Menschen stammt.
15. Verfahren gemäß Anspruch 1 zum Nachweis von humanem Harnblasen- und Cervixkarzinom.
16. Verfahren gemäß Anspruch 1 zum Nachweis von Lungen-, Brust-, Dickdarm- und Hautkrebs.
17. Verwendung eines gegen FGFR3 gerichteten Antikörpers zur Herstellung eines Medikaments zur Behandlung von Karzinomen.
18. Verwendung gemäß Anspruch 17, wobei der Antikörper monoklonal ist.
19. Verwendung gemäß Anspruch 17, wobei der Antikörper humanisiert ist.
20. Verwendung von Antisense-Oligonucleotiden, die gegen eine Wildtyp- oder mutierte FGFR3-Isoform gerichtet sind, zur Herstellung eines Medikaments zur Behandlung von Karzinomen.
21. Verwendung gemäß Anspruch 17 bis 20, wobei es sich bei den Karzinomen um Cervix- oder Harnblasenkarzinome handelt.

22. Transgènes Tier ausschließlich des Menschen, das ein Konstrukt umfasst, welches einen Keratinpromotor und cDNA von mutiertem FGFR3 umfasst und die Expression eines mutierten FGFR3 erlaubt, der ins Epithel gelenkt wird.

5 **Revendications**

1. Procédé de détection de carcinomes dans un échantillon biologique, comprenant l'identification de mutations de FGFR3.
- 10 2. Procédé selon la revendication 1, comprenant le criblage d'une ou plusieurs mutations ponctuelles dans des acides nucléiques du groupe comprenant l'ADN génomique, l'ARN ou l'ADNc.
3. Procédé selon la revendication 1, comprenant le criblage d'une ou plusieurs mutations ponctuelles dans des protéines.
- 15 4. Procédé selon la revendication 1, comprenant le criblage de mutations créant des résidus cystéine dans les domaines transmembranaires ou extracellulaires du récepteur.
5. Procédé selon la revendication 1, comprenant le criblage de mutations entraînant au moins une substitution d'acide aminé dans le domaine kinase du récepteur.
- 20 6. Procédé selon la revendication 5, comprenant le criblage de mutation(s) activatrice(s) de FGFR3.
7. Procédé selon la revendication 6, comprenant le criblage de mutation(s) activatrice(s) de FGFR3-IIIb.
- 25 8. Procédé selon la revendication 1, comprenant le criblage de mutation(s) dans le groupe comprenant l'exon 7, qui code pour la jonction entre les domaines II et III de type immunoglobuline de FGFR3, l'exon 10, qui code pour le domaine transmembranaire, l'exon 15, qui code pour le domaine tyrosine-kinase I, et l'exon qui code pour la partie C-terminale.
- 30 9. Procédé selon la revendication 1, comprenant le criblage de mutations faux-sens telles que celles impliquées dans la dysplasie thanatophore, NSC, l'achondroplasie, SADDAN ou l'hypochondroplasie.
- 35 10. Procédé selon la revendication 9, dans lequel les mutations comprennent R248C, S249C, G372C, S373C, Y375C, K652E, K652M, J809G, J809C, J809R, J809L, P250R, G377C, G382R, A393E et N542K.
11. Procédé selon la revendication 9, comprenant le criblage des mutations R248C, S249C, G372C, K652E et Y375C.
- 40 12. Procédé selon la revendication 1, dans lequel l'échantillon biologique est choisi dans le groupe comprenant un tissu, de la moelle osseuse ou un fluide corporel.
13. Procédé selon la revendication 12, dans lequel ledit fluide corporel est choisi dans le groupe comprenant le sang ou l'urine d'un animal à sang chaud.
- 45 14. Procédé selon la revendication 13, dans lequel ledit fluide corporel provient d'un être humain.
15. Procédé selon la revendication 1 de détection de carcinomes de cols de l'utérus et de la vessie chez un être humain.
- 50 16. Procédé selon la revendication 1 de détection de cancers du poumon, du sein, du colon et de la peau.
17. Utilisation d'un anticorps dirigé contre FGFR3 pour la fabrication d'un médicament pour le traitement de carcinomes.
18. Utilisation selon la revendication 17, dans laquelle l'anticorps est monoclonal.
- 55 19. Utilisation selon la revendication 17, dans laquelle l'anticorps est humanisé.
20. Utilisation d'oligonucléotides anti-sens dirigés contre une isoforme de FGFR3 mutée ou de type sauvage pour la fabrication d'un médicament pour le traitement de carcinomes.

EP 1 208 231 B1

21. Utilisation selon les revendications 17 à 20, dans laquelle lesdits carcinomes sont des carcinomes du col de l'utérus ou de la vessie.
22. Animal transgénique à l'exclusion d'un être humain comprenant une construction qui comprend un promoteur de la kératine et de l'ADNc de FGFR3 muté permettant l'expression d'un FGFR3 muté dirigée dans l'épithélium.

5

10

15

20

25

30

35

40

45

50

55

FIGURE 1





Figure 2A

Wild Type FGFR3-IIb:

ATGGGCGCCCTGCCTGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC
 GGAGCAGCGCGTCTGGGGCGAGCGGCAGAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACCCGTCCGCTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCAGCACCCGATGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGAAAGCGTGGTCCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCCGACCGGCCCATCCTGCAGGCGGGGCTGCCGGCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCCTACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGGCCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTCATAGGCGTGGC
 CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCCTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGEAGGCCATCGGCATTEACAAGGACCGGGCCGCAAGCCTGTACCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAACACAAAACATCATCAACCTGCTGGGCGCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGGC
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTCAAGGACCTGGTGTCTGTGCCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGA
 AGTGCATCCACAGGGACCTGGTGCCTGCAATGTGTGGTACCAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG
 GCTCCCCGTACCCGGCATCCCTGTGGAGGAGCTCTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGCGGCGCTTTCGAGCAGTACTCCC
 CGGGTGGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCGGGCCCA
 CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2B

Mutant R248C FGFR3-IIIb:

ATGGGGCCCCCTGCCTGCSCCCTCGCGCTCTGCGTGGCCATCGTGGCCGGCCCTCCTCGGAGTCCTTGGGGAC
 GGAGCAGCGCTCGTGGGGCAGCGGCAGAAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCGGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGGAGCGTGTCTGTTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCCSAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCCGCGGGCAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTGCCTCGGACCGCGGCCAACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGTGTCTCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCCTACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCTGGATCAGTGAGAGTGTGGAGCCGAC
 GTGCGCCTCCGCTGSCCAATGTGTGCGAGCGGGACGGGGCGAGTACCTCTGTCGAGCCACCAATTTTCATAGGCGTGGC
 CGAGAAGGCCTTTTGGCTGAGCGTTACGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCCTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCGGCTGACCTGGGCAAGCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCCAAGCCTGTACCCTG
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGG
 GCCAAGGGTAACCTGCGGGAGTTTCTCGGGCGCGGGCCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCAG
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGAACGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGGACGTGCAACCTCGACTACTACAAGAAGACAACCAACGGCCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG
 GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCAAC
 TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCC
 CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCAGACCTGCTGCCCCCGGCCCA
 CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2c

Mutant S249C FGFR3-IIIb:

ATGGGCGCCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCCTGGGGAC
 GGAGCAGCGCGTCTGTGGGGCGAGCGGCAGAACTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGGCCCTCGGAGCGTGTCTGGTGGGSCCCAGCGGTGCAGGTGCTGAATGCCTCCACAGGAGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCCCTTACTGGACACGGCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACAACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCAGCACCGCATTTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAGCGTGGTGGCCCTCGGACCGCGGCAACTACACCTGCGTCTGGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTGCCCGCACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCACCTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCCCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGCGCCTCCGCTGGCCAATGTGTCGGAGCGGGACGGGGCGGAGTACCTCTGTGAGCCACCAATTCATAGGCGTGGC
 CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCGGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGACGGCATCCTCAGCTACGGGTGGGCTTCTTCTGTTTCCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTG
 CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGGCTCCATGAGCTCCAACACACCCTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTCAAGGGGAGGCCATCGGCATTGACAAGGACCGGGCCCAAGCCTGTACCCTG
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAACACAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGGC
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCTCCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCTGAGGC
 CTGTTTACCAGTCTACACTCACCAGAGTACGCTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG
 GCTCCCCGTACCCCGCATCCCTGTGGAGGAGCTCTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGACACACAGCCTGTACATGATCATGCGGGAGTGTGGCATGCCCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCC
 CGGGTGGCCAGGACACCCCCAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCCGGCCCCA
 CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2D

Mutant G372C FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCCCTCCTCGGAGTCCCTGGGGAC
 GGAGCAGCGCGTCCGTGGGGCGAGCGGCAGAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCGCCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGGCCCTCGGAGCGTGTCTGGTGGGGCCCGAGCGCTGCAGGTGCTGAATGCCCTCCACAGGAGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGGGGTACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCSCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTCCGGGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTGGCCCTCGGACCGCGGCAACTACACCTGCGTGGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCGCACCGGGCCATCCTGCAGGGCGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCCTACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCCGACGGCACACCCTACGTTACCGTGTCAAGTCCCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGGCCCTCCGCTGGCCAATGTGTCCGAGCGGACGGGGCGAGTACCTGTCTCGAGCCACCAATTCATAGGCTGGC
 CGAGAAGGCCCTTTGGCTGAGCGTTACCGGGCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGTGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCAAATGGGAGTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCCCT
 GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGAAACACAAAAACATCATCAACCTGCTGGCGCCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGCG
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGGGCCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTACCAGGACCAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGG
 GCTCCCCGTACCCCGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCCGCCAAC
 TGACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTCCGGCGCTTTCGAGCAGTACTCC
 CGGGTGGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCGGGCCCCA
 CCCAGCAGTGGGGCTCGCGGACGTGA

Figure 2E

Mutant K652E FGFR3-IIib:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC
 GGAGCAGCGCGTCTGGGGCGAGCGGCAGAAGTCCCAGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCGCGCCGGGGTGGTCCCATGGGGCCCACTGTCTGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCAACACCGTCCGCTTCCGCTGCCAGCGGCTGGCAACCCCACTCCCTCCATCTC
 CTGGTGAAGAACGGCAGGGAGTTCGCGGGCAGCACCAGCATGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTCCCTCGGACCGCGGCACTACACCTGCGTGGAGAACAAAGTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCCGACCGGCCATCCTGCAGGCGGGGCTGCCGGCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCACCTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCAGCTGGAGGTGA
 ACGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCCCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGCGCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTCATAGGCGTGGC
 CGAGAAGGCCTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGCTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCGCTTCCGCTCAAGCAGAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCAGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT
 GGGGAGGCTGCTTCGGCCAGGTGGTCAATGGCAGGAGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAACACAAAACATCATCAACTGCTGGGCGCCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGG
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCCCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGA
 AGTGCATCCACAGGGACCTGGTGGCCGCAATGTGCTGGTACCAGGACAACGATGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGACGTGCACAACCTCGACTACTACAAGGAGACAACCAACGGCCGGCTGCCGCTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTCACAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCAGCTGGGGG
 GCTCCCCGTACCCCGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGCACACAGCAGCTGTACATGATCATGCGGGAGTGTGGCATGCCCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGGCGCCTTTCGAGCAGTACTCC
 CGGGTGGCCAGGACACCCAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCGGGCCCCA
 CCCAGCAGTGGGGCTCGCGGACGTGA

Figure 2F

Mutant S373C FGFR3-IIb:

ATGGGCGCCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC
 GGAGCAGCGCGTCTGGGGCGAGCGGCAGAAAGTCCCAGGCCCCAGAGCCCCGAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCAGAGG
 CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCCCTTACTGGACACGGCCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACCCGTCGCGCTTCCGCTGCCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCGGCGGGCAGCACCCGATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGAAAAGCGTGGTGCCTCGGACCGCGGCACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCCGACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCGGACGGCACACCCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGGCCTCCGCTGGCCAAATGTGTGCGAGCGGGACGGGGCGAGTACCTGTGCGAGCCACCAATTTATAGGCGTGGC
 CGAGAAGCCCTTTTGGCTGAGCGTTACGGGCCCGGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCTGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTATCCTGGTGGTGGCGGTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGSCCTGGGCTCCCCCACCCTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACCGTCCATGAGCTCCAACACACCACTGGTGGCCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGAGCTGTCTCGGGCCCCGGTGAACCTGGGCAAGCCCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTCTATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTCACCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGAAACACAAAACATCATCAACCTGCTGGCGCCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGG
 GCCAAGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTCAAGGACCTGGTGTCTGTGCTACCAGTGGCCCCGGGGCATGGAGTACTTGGCCTCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGGTACCAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTCACAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACCGCTGGGGG
 GCTCCCCGTACCCGGCATCCCTGTGGAGGAGCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGCACACAGCAGCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTCCGGCGCCTTTCGAGCAGTACTCC
 CGGGTGGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGCCACGACCTGCTGCCCGGGCCCCA
 CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 26

Mutant Y375C FGFR3-II_b:

ATGGGCGCCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTGGAGTCCTTGGGGAC
 GGAGCAGCGCGTCTGTTGGGGCGAGCGGCAGAAAGTCCCAGGGCCAGAGCCCGCCAGCAGGAGCAGTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGEAGCGTGTCTGTTGGGGCCCGAGCGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGGGGTACAGACGCTCCATCCTCGGGAGATG
 ACCAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCSCTGGCAACCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCCGCGGGCAGCACCAGCATTGGAGGCATCAAGCTGGCGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTGCCTCGGACCGGGCAACTACACTGCGTGGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCGCACCGGCCATCCTGCAGGCGGGGCTGCCGGCAACCAAGCAGCGCGGTGCT
 GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTACCCTGCTCAAGTCCCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGCGCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTATAGGGCTGGC
 CGAGAAGGCCCTTTGGCTGAGCGTTCACGGGCCCGAGCAGCCGAGGAGGAGTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTGTGAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCCTGGTGGCGATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCCTG
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAACACAAAAACATCATCAACCTGCTGGGCGCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGGC
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCCTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTCACCAGAGTGAGCTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG
 GCTCCCCGTACCCCGGCATCCTGTGGAGGAGCTTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGCACACAGCCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTCCGGCGCTTTCGAGCAGTACTCCC
 CGGGTGGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCAGGACCTGCTGCCCGGGCCCA
 CCCAGCAGTGGGGCTCGCGGACGTGA

Figure 2H

Mutant K652M FGFR3-IIib:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCCTCCTCGGAGTCCTTGGGGAC
 GGAGCAGCGCGTCTGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCAGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACAGGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCCGCGGGCAGCACCCGATGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGCGCCTCCGCCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTTCATAGGCGTGGC
 CGAGAAGGCCCTTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGCTGTTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCSTGCACAAGATCTCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCCTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATGACAAGGACCGGGCCGCCAAGCCTGTACCCTG
 AGCCGTGAAGATGCTGAAGACGATGCCACTGACAAGGACCTGTGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAACACAAAAACATCATCAACCTGCTGGGCGCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGG
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGGACGTGCACAACCTCGACTACTACAAGATGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG
 GCTCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGCACACAGACCTGTACATGATCATGCGGGAGTGTGGCATGCCCGGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGGCGCCTTTCGAGCAGTACTCCC
 CGGGTGGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTSCCCACGACCTGCTGCCCGGGCCCA
 CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2I

Mutant X809C FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCCTGGCCGGCGCCTCCTCGGAGTCCCTGGGGGAC
 GGAGCAGCGCGTCTGTTGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCGGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGTTGCCCTCGGAGCGTGTCTGGTGGGGCCCGAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGSGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCAGCACCCTTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTCTGTTGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCCGCCACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCAGCTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCTACGTTACCGTGTCAAGTCCCTGGATCAGTGAGAGTGTGEAGGCCGAC
 GTGCGCCTCCGCTGGCCAATGTGTGCGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTTATAGGCGTGGC
 CGAGAAGGCCTTTTGGCTGAGCGTTACGCGGCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGCCTGGGCTCCCCACCGTGACAAGATCTCCGCTTCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGECATCGGCATGACAAGGACCGGGCCGCAAGCCTGTACCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAACACAAAAACATCAACCTGCTGGGCGCTGCACGAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGCCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCCATACCAGTGGCCCCGGGCATGGAGTACTTGGCCTCCAGA
 AGTGCATCCACAGGACCTGGCTGCCCGCAATGTGCTGGTGAACGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGSCCGGCTGCCGTAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG
 GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCCCAAC
 TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTCCGGCGCCTTTCGAGCAGTACTCC
 CGGGTGGCCAGGACACCCCACTCCAGTCCCTCAGGGGACGACTCCGTGTTTCCCACGACCTGCTGCCCGGGCCCA
 CCCAGCAGTGGGGCTCGCGGACGTGC

Figure 2J Mutant 1

Mutant X809G EGFR3-IIIb:

ATGGGGCCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCCSCTCCTCGGAGTCTTGGGGAC
 GGAGCAGCGCGTCTGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTG3TCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCGCGCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGGAGCGTGTCTGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCAGCGAGCGCTACTGTCCACTTCAGTGTGCGGGTACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGSCCCTTACTG5ACACGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCSTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTGCCTC5GACCCGCGCAACTACACTGCGTGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCGCACCGGCCATCCTGCAGGGCGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCCTGCAAGGTGTACAGTGACGCACAGCCCACTCCAGTGGCTCAAGCACSTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCTGGATCAGTGAAGTGTGGAGGCCGAC
 GTGGCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTCATAGGCGTGGC
 CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGCGGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTG
 CGCAGCCCCCAAGAAAGGCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGCAGAGGTGTCCCT
 GGAGTCCAACCGTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT
 AGCGGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAACACAAAACATCATCAACCTGTGGGCGCCTGCACGCAAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG
 GCCAAGGTTAACCTGCGGGAGTTTCTGCGGGCGGGCGGGCCCCGGGCTGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTCAAGGACCTGGTGTCTGTGCTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTACCAGGAGACAACCTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG
 GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGCACACAGCAGCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCAGCAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCCC
 CGGGTGGCCAGGACCCCCAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA
 CCCAGCAGTGGGGCTCGCAGGACGGGA

Figure 2K Mutant 2

Mutant: X809G FGFR3-IIib:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCCTCCTCGGAGTCCCTGGGGAC
 GGAGCAGCGCTCGTGGGGCGAGCGGCAGAAAGTCCCCGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCCGAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGGAGCACCGCATGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCGCACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCACCTGCAAGGTGTACAGTGACGCACAGCCCAATCCAGTGGCTCAAGCAGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCTACGTTACCGTCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGCGCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTCATAGGCGTGGC
 CGAGAAGGCCTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCTCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTG
 CGCAGCCCCCAAGAAAGGCTGGGCTCCCCACCGTGCACAAGATCTCCGCTTCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT
 AGCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCGGGCCCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTACCAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGCTCTGCTCTGGGAGATCTTACGCTGGGG
 GCTCCCCGTACCCCGCATCCCTGTGGAGGAGCTCTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCAAC
 TGACACACGACCTGTACATGATCATGCGGGAGTGGTGGCATGCCCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTCCGGCCCTTTCGAGCAGTACTCCC
 CGGGTGGCAGGACACCCAGCTCCAGCTCCTCAGGGACGACTCCGTGTTTGCACACGACCTGCTGCCCCGGCCCCA
 CCCAGCAGTGGGGCTCGCGGACGAGA

Figure 2L Mutant 3

Mutant: X909G FGFR3-IIIb:

ATGGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGCCCGTGGCCATCGTGGCCGGCCCTCCTCGGAGTCCTTGGGGAC
 GGAGCAGCGCGTGGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCAGAGG
 CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCCGAGCGGCTGCAGGTGCTGATGCTCCACAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGGGGTGCAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCGCGTGCACAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCGGCGGGCAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTGCCTCGGACCGCGCAACTACACTGCGTGGAGAAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCCGACCCGGCCATCCTGCAGGGCGGGCTGCCGGCAACCAGACGGCGGTGCT
 GGGCAGCGCAGTGGAGTTCCTGCAAGGTGTACAGTGCAGCAGCCCACTCCAGTGGCTCAAGCAGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGCGCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGGCGAGTACCTCTGTGAGCCACCAATTCATAGGCGTGGC
 CGAGAAGGCCTTTTGGCTGAGCGTTACGGGCCCGGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCCGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCTGGGCTCCCCACCGTGCACAAGATCTCCGCTTCGCGCTCAAGCGACAGGTGTCCCT
 GGATCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCAGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT
 GGGAGGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCCT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGAAACACAAAAACATCATCAACCTGTGGCGCCTGCAGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGG
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGGCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCCGAGACTTCGGGCTG
 GCCCGGACGTGCAACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTGTTTTGACCGAGTCTACACTCACAGAGTGCAGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGG
 GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTTTCAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGCACACAGCCTGTACATGATCATGCGGGAGTGTGGCATGCCCGCCCTCCAGAGGCCCACTTCAAGCAGCTGGT
 GGAGACCTGGACCGTGTCTTACCGTACCTCCACCGACGAGTACCTGGACCTGTGGCGCCTTTCGAGCAGTACTCCC
 CGGGTGGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCGGGCCCA
 CCCAGCAGTGGGGCTCGCGGACGCGA

Figure 2M

Mutant X909L FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC
 GGAGCAGCGCCTCGTGGGGCGAGCGGCAGAAGTCCCCGGCCCGGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAAGTGTGAATGCCTCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGGGGTGCAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACCCGTCGCGTTCGCGTGGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTGTGGAGAACAAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCCGACCGGCCCATCTGCAGGGGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCCTGCAAGGTGTACAGTGCAGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCCCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGCGCCTCCGCTGGCCATGTGTGGAGCGGACGGGGGGGAGTACCTCTGTGAGCCACCAATTTATAGGCGTGGC
 CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCTGGGCTCCCCACCGTGCACAAGATCTCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCSCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCAGCGAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGG
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCCTACCAGTGGCCCCGGGCATGGAGTACTTGGCCTCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTCACCAGAGTGCAGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG
 GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCCCAAC
 TGACACACAGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCGTGCAGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTGAGCAGTACTCCC
 CGGGTGGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA
 CCCAGCAGTGGGGCTCGCGGACGTTA

Figure 2N Mutant 1

Mutant N542K FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC
 GGAGCAGCGCGTCTGGGGCGAGCGGCAGAAGTCCCAGGGCCAGAGCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACCCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCCGCGGGCAGCACCCGATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCCTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGCCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCTGGATCAGTGAAGTGTGGAGGCCGAC
 GTGCGCCTCCGCTGGCCAATGTGTGCGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTTCATAGGCGTGGC
 CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACCGCTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCCT
 GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAACACAAAAACATCATCAAAGTGTGGGCGCCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG
 GCCAAGGGTAACCTGCGGGAGTTTCTCGGGCGCGGGCGCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGG
 GCTCCCCGTACCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCAAC
 TGACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTCCGGCGCCTTTCGAGCAGTACTCCC
 CGGGTGGCAGGACACCCCGAGTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCAGACCTGCTGCCCCGGGCCCA
 CCCAGCAGTGGGGCTCGCGGACGTGA

Figure 20 Mutant 2

Mutant N542K FGF23-IIIb:

ATGGGCGCCCTGCGCCCTGGCGCTCTGCGTGGCCCTGGCCATCGTGGCCGGCGCCCTCCTCGGAGTCCCTGGGGAC
GGAGCAGCGCGTCTGTTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAATTGGTCTTCGGCAGCG
GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCAGAGG
CTGGTGGCCCTCGGAGCGTGTCTGGTGGGGCCCGAGCGGTGCAGGTCTGAATGCCTCCACAGAGGACTCCGGGGCCTA
CAGCTGCCGGCAGCGGCTCAGCGAGCGCGTACTGTGCCACTTCAGTGTGGGGTGGACAGAGCGTCCATCCTCGGGAGATG
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
CTGGCTGAAGAAGCGGAGGAGTTCGGCGGGCAGCACCCGATGGAGGCATCAAGCTGGGGCATCAGCAGTGGAGCCTGG
TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACTGCCTCTGGAGAAACAAGTTTGGCAGCATCCGGCAGACG
TACACGCTGGACGTGCTGGAGCGCTCCCCGACCGGGCCATCCTGCAGGGGGGCTGCCGGCCAAACCAGACGGCGGTGCT
GGGCAGCGACGTGGAGTCCACTGCAAGGTGTACAGTACAGCACAGCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
ACGGCAGCAAGGTGGGCCCGGACGSCACACCCCTACGTTACCGTGTCAAGTCTGGATCAGTGGAGTGTGGAGGCCGAC
GTGGCCTCCGCTGGCCAAATGTGTGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTTATAGGCGTGGC
CGAGAAGGCCCTTTTGGCTGAGCGTTCACGGGCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
CGCAGCCCCCCCAAGAAAGGCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
CCAATGTCTCCGAGCTCGAGCTGCCTGCCACCCCAATGGGAGTGTCTCGGGCCGGCTGACCCTGGGCAAGCCCTT
GGGGAGGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGCCATCGGCATTCACAAGGACCGGGCCGCCAAGCCTGTACCGT
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
TCGGGAAACACAAAAACATCATCAAGCTGCTGGGCGCTGCACGAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGGC
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGGCCCGGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAAGTGGCCCGGGCATGGAGTACTTGGCCTCCAGA
AGTGCATCCACAGGACCTGGCTGCCCGCAATGTGCTGGTACCAGGACACAGTGAATGAAGATCSCAGACTTCGGGCTG
GCCCCGGACGTGCAACCTCGACTACTACAAGAAGCAACCAACGGCCGGCTGCCGTGAAGTGGATGGCGCTGAGGC
CTTGTTEACCGAGTCTACTACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTTCTCTGGGAGATCTTACGCTGGGG
GCTCCCCSTACCCCGCATCCCTGTGGAGGAGCTCTCAAGCTGCTGAAGGAGGGCCACCCGATGGACAAGCCCGCCAA
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCCACTTCAAGCAGCTGGT
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGGCGCCCTTTCGAGCAGTACTCCC
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTCCCCACGACTGCTGCCCGGGCCCA
CCCAGCAGTGGGGCTCGCGGACGTGA

Figure 2P Mutant 1

Mutant G382R FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCTTGGGGAC
 GGAGCAGCGCGTCTGTTGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTCCCGGGCGAGCACCGCATGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCAATGGAAAAGCTGGTGCCTCGGACCGCGGCAACTACACCTGCGTGGGAGAAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCGCACCGGCCATCCTGCAGGGGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCACCTGCAAGGTGTACAGTACGCGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCCCTGGATCAGTGAAGTGTGGAGGCCGAC
 GTGGCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTGTGCGAGCCACCAATTCATAGGCGTGGC
 CGAGAAGGCCTTTGGCTGAGCSTTACGGGCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
 TGTATGCAGGCATCCTCAGCTACAGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCTGGGCTCCCCACCGTGCACAAGATCTCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACCGCTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAACACAAAACATCATCAACCTGCTGGCGCCTGCACGAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGGC
 GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGTCACTTCAAGGACCTGGTGTCTGTGCCTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCCAGA
 AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTGACCGAGTCTACACTCACCAGAGTACGCTTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG
 GCTCCCCGTACCCCGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TSCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGCT
 GGAGGACCTGGACCGTGTCTTACCCTGACGTCACCGACGAGTACCTGGACCTGTGGCGCCTTTCGAGCAGTACTCCC
 CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCCCGGCCCA
 CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2Q Mutant 2

(

-

Mutant G382R FGFR3-IIIb:

)

(

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCCTCCTCGGAGTCCTTGGGGAC
GGAGCAGCGCGTCTGGGGCGAGCGGCAGAAAGTCCCAGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG
CTGGTGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA
CAGTGTCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGGGGTGACAGACGCTCCATCCTCGGGAGATG
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCGAGCGGATGGAC
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
CTGGCTGAAGAACGGCAGGGAGTCCCGGGCGAGACCCGATGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTCTGGGAGAACAGTTTGGCAGCATCCGGCAGACG
TACACGCTGGACGTGCTGGAGCGCTCCCGCACCGGCCATCCTGCAGGGGGGCTGCCGGCAACCAGACGGCGGTGCT
GGGCAGCGACGTGGAGTTCACACTGCAAGGTGTACAGTACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC
GTGCGCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTCTGTCGAGCCACCAATTCATAGCGGTGCC
CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
TGTATGCAGGCATCCTCAGCTACCGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
CGCAGCCCCC CAAGAAAGGCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCAGCAGGTGTCCCT
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
CCAATGTCTCCGAGCTCGAGTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCTTGGGCAAGCCCTT
GGGGAGGGCTGCTTCGGCCAGGTGGTGCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCCT
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
TCGGGAAACACAAAACATCATCAACCTGCTGGGCGCTGCACGAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGGGCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCCTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCCGA
AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCAGGACAACTGATGAAGATCGCAGACTTCGGGCTG
GCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCTGAGGC
CTTGTGTTGACCGAGTCTACTACTACCAGAGTGACGTCTGGTCTTTGGGTCTGCTCTGGGAGATCTTACCGCTGGGG
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGTGGT
GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGGGSCCTTTCGAGCAGTACTCC
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCCGGCCCA
CCCAGCAGTGGGGCTCGCGGACGTGA

Figure 2R

Mutant G377C FGFR3-IIib:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCCTCCTCGGAGTCCTTGGGGAC
 GGAGCAGCGCGTCTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCCAACACCCTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTTCGCGGGGAGCACCCGATTGGAGGCATCAAGCTCGGGCATCAGCAGTGGAGCCTGG
 TCATGAAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCCGCAACGGCCCATCTGCAGGGCGGGCTGCCGGCAACCAGACGGCGGTGCT
 GGCAGCGACGTGGAGTTCCTGCAAGGTGTACAGTGACGCACAGCCCAATCCAGTGGCTCAAGCACGTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGGCCCTCCGCTGGCCAATGTGTGCGAGCGGGACGGGGCGGAGTACCTCTGTCGAGCCACCAATTTTCATAGGCGTGGC
 CGAGAAGCCCTTTGGCTGAGCGTTACGGGCCCGGACGCGCGAGGAGGAGCTGGTGGAGGCTGACGAGCGGGCAGTG
 TGTATGCATGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCCTGCACAAGATCTCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACCGCTCCATGAGCTCCAACACACCCTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCACCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAAACAAAAACATCATCAACCTGCTGGGCGCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGG
 GCCAAGGGTAACCTGCGGGAGTTCGCGGGCGGGCGGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTCAAGGACCTGGTGTCTGTGCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGA
 AGTGATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
 GCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGCCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTTACCGAGTCTACACTACCCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGG
 GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCCACTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGGCGCCCTTCGAGCAGTACTCCC
 CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCGGGCCCA
 CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 25

Mutant A393E FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCSTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC
GGAGCAGCGCTCGTGGGGCGAGCGGCAGAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCGGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGGGGTGACAGACGCTCCATCCTCGGGAGATG
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACCCGTCCGCTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
CTGGTGAAGAACGGCAGGGAGTCCGCGGGCAGCACCGCATGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG
TACACGCTGGACGTGCTGGAGCGCTCCCCGACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCT
GGGCAGCGAGCTGGAGTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA
ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGCCGAC
GTGGCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCCAGTACCTCTGTGAGCCACCAATTCATAGGCGTGGC
CGAGAAGGCCTTTTGGCTGAGCGTTCAGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGAGGCTGTGACGCTCTGCCGCTG
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
GGAGTCCAACCGCTCCATGAGCTCCAACACACCCTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT
GGGGAGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCCT
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
TCGGGAAACACAAAACATCATCAACTGCTGGGCGCCTGCACGAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGG
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGGGCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCAGA
AGTGATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTACCAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG
GCCCCGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCTGAGGC
CTTGTGTTGACCGAGTCAACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACCGTGGGG
GCTCCCCGTACCCCGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCCCAAC
TGACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGGCCACCTTCAAGCAGCTGGT
GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGGCGCCTTTCGAGCAGTACTCC
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCCGGCCCCA
CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2T

Mutant P250R FGFR3-IIIb:

ATGGGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCCTTGGGGAC
 GGAGCAGCGCGTCTGTGGGGCGAGCGGCAGAAAGTCCCAGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG
 GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG
 CTGGTGGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA
 CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCACTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG
 ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC
 AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC
 CTGGCTGAAGAACGGCAGGGAGTCCGCGGGCAGCACCAGTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG
 TCATGGAAGCGTGGTGGCCCTCGGACCGCGGCAACTACACCTGCGTGGGAGAACAAGTTTGGCAGCATCCGGCAGACG
 TACACGCTGGACGTGCTGGAGCGCTCCCGGCACCGGCCATCCTGCAGGGGGGCTGCCGGCCAACCAGACGGCGGTGCT
 GGGCAGCGACGTGGAGTTCCTGCAAGGTGTACAGTGACGCACAGCCCACTCCAGTGGCTCAAGCAGCTGGAGGTGA
 ACGGCAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC
 GTGCGCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTGTGCGAGCCACCAATTCATAGGCGTGGC
 CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGCAGTG
 TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG
 CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT
 GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGG
 CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCTT
 GGGGAGGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCCAAGCCTGTACCGT
 AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA
 TCGGGAAACAAAAACATCATCAACCTGCTGGGCGCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGGC
 GCCAAGGTTAACCTGCGGGAGTTCTGCGGGCGGGCGGGCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC
 CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCAGA
 AGTGATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTGGGGCTG
 GCCCGGACGTCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC
 CTTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG
 GCTCCCCGTACCCCGCATCCCTGTGGAGGAGCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC
 TGCACACAGACCTGTACATGATCATGCCGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT
 GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGGCGCTTTCGAGCAGTACTCC
 CGGGTGGCCAGGACACCCCACTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCCCGGCCCA
 CCCAGCAGTGGGGGCTCGCGGACGTGA

FIGURE 3

